var title_f26_49_27408="RIDTs during periods of low influenza activity";
var content_f26_49_27408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Algorithm to assist in the interpretation of rapid influenza diagnostic test (RIDT) results and clinical decision-making during periods when influenza viruses are not circulating or influenza activity is low in the community*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RIDT: rapid influenza diagnostic test.",
"     <br>",
"      * During periods when influenza activity is low and there is low influenza virus circulation among persons in the community, the positive predictive value of a rapid influenza diagnostic test is low (that is, the chance that a positive result indicates that the patient has influenza is low), and the negative predictive value is high (the chance that a negative result is a true negative is high). Even though RIDTs have high specificity, false positive RIDT results are more common when influenza activity is low.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Influenza virus infection may include seasonal influenza A (H3N2), 2009 H1N1, influenza B, or rarely, a novel influenza A virus infection. The interpretation of RIDTs will, in part, depend on the test used - some will detect influenza A, some will detect influenza B, and some will detect both A and B viruses. If tests for both influenza A and influenza B are positive, refer specimen to a public health laboratory for resolution, as dual infections are uncommon.",
"       <br>",
"        &Delta; Consult local or state health departments or other sources (eg, virology testing at a local hospital) for local activity on other respiratory pathogens associated with acute respiratory illness. Empiric antibiotic coverage should include coverage for",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        ,",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"        (including methicillin-resistant",
"        <em>",
"         S. aureus",
"        </em>",
"        ), Group A streptococci, and others, especially for hospitalized adult patients per the Infectious Diseases Society of America/American Thoracic Society community-acquired pneumonia (CAP) guidelines.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     United States Centers for Disease Control and Prevention. Guidance for clinicians on the use of rapid influenza diagnostic tests.&nbsp;",
"     <a href=\"file://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm\" target=\"_blank\">",
"      file://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm",
"     </a>",
"     (Accessed on April 6, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27408=[""].join("\n");
var outline_f26_49_27408=null;
var title_f26_49_27409="Amniotic band sequence with abdominal wall defect";
var content_f26_49_27409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amniotic band sequence with abdominal wall defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal image through the fetal body shows disruption of the anterior abdominal wall with the abdominal contents (arrows) extruding out.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27409=[""].join("\n");
var outline_f26_49_27409=null;
var title_f26_49_27410="Cytology brush for ERCP";
var content_f26_49_27410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cytology brush used during ERCP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cytology brush immediately after obtaining biliary samples. The head of the brush was cut and sent to pathology after being placed in fixative.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Isaac Raijman, MD, and Susana Escalante-Glorsky, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27410=[""].join("\n");
var outline_f26_49_27410=null;
var title_f26_49_27411="Diatrizoate meglumine and iodipamide meglumine: Patient drug information";
var content_f26_49_27411=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diatrizoate meglumine and iodipamide meglumine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44338?source=see_link\">",
"     see \"Diatrizoate meglumine and iodipamide meglumine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sinografin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an x-ray of the uterus and fallopian tubes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701930",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to diatrizoate meglumine, iodipamide meglumine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a contrast dye allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an iodine allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Genital infection or have your period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or time is within 6 months after pregnancy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699109",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be put into the cervix by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11627 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-59F4F6E9F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27411=[""].join("\n");
var outline_f26_49_27411=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159614\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025959\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025958\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025962\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025963\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025965\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025961\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025966\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025967\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44338?source=related_link\">",
"      Diatrizoate meglumine and iodipamide meglumine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_49_27412="Vulvovaginal lichen planus";
var content_f26_49_27412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvovaginal lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vulvar erosions and perianal papules due to lichen planus are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Bethanee Schlosser.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27412=[""].join("\n");
var outline_f26_49_27412=null;
var title_f26_49_27413="Glipizide and metformin: Patient drug information";
var content_f26_49_27413=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Glipizide and metformin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/37/39510?source=see_link\">",
"     see \"Glipizide and metformin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Metaglip&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A small number of people may have more acid in their blood. Metformin may cause this. It may happen in people whose liver or kidneys do not work the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702205",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glipizide, metformin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem, drink too much alcohol, fluid loss, kidney disease, liver disease, or very weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having an x-ray with dye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop this drug for 2 days after you have an x-ray with dye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you are having surgery, if you have had a heart attack, bad infection, or stroke, or if you are 80 years of age or older and have not had your kidney function tested.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much acid in the blood (lactic acidosis) may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with other high blood sugar (diabetes) drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12512 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-581423BC0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27413=[""].join("\n");
var outline_f26_49_27413=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176413\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022590\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022592\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022591\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022596\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022597\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022599\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022594\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022595\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022600\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022601\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/37/39510?source=related_link\">",
"      Glipizide and metformin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_49_27414="Neurologic manifestations of Fabry disease";
var content_f26_49_27414=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic manifestations of Fabry disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27414/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27414/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27414/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27414/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27414/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27414/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27414/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/49/27414/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fabry disease (also called angiokeratoma corporis diffusum, ceramide trihexosidosis, and Anderson-Fabry disease) is an X-linked recessive glycolipid storage disease. It is caused by deficient activity of the lysosomal enzyme alpha-galactosidase A, which causes progressive accumulation of globotriaosylceramide (the glycolipid substrate for alpha-galactosidase A) within vulnerable cells and tissues of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Numerous mutations have been found in the alpha-galactosidase A gene (GLA gene) on the long arm of the X chromosome (Xq22) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations usually become evident by 10 years of age. Initial manifestations typically include neuropathy and characteristic skin lesions known as angiokeratomas. As patients age, cardiovascular and renal disease become increasingly prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/6\">",
"     6",
"    </a>",
"    ]. An overview of the clinical manifestations of Fabry disease and other related disorders in presented in the Table (",
"    <a class=\"graphic graphic_table graphicRef56567 \" href=\"UTD.htm?36/27/37308\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Progressive accumulation of globotriaosylceramide within endothelial, perithelial, and smooth muscle cells of the vascular system, dorsal root ganglia and cells of the autonomic nervous system, result in the neurologic manifestations of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/2\">",
"     2",
"    </a>",
"    ]. These include peripheral neuropathy and cerebrovascular complications in affected males and female carriers.",
"   </p>",
"   <p>",
"    This topic will review the neurologic manifestations of Fabry disease and their treatment.",
"   </p>",
"   <p>",
"    Other clinical aspects of Fabry disease are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=see_link\">",
"     \"Clinical features and diagnosis of Fabry disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=see_link\">",
"     \"Treatment of Fabry disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=see_link\">",
"     \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERIPHERAL NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy associated with Fabry disease causes an almost constant discomfort of the hands and feet, with paroxysmal burning pains of the palms and soles [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/7\">",
"     7",
"    </a>",
"    ]. Recurrent painful episodes may be triggered by stress, fever, heat, fatigue, joint pain or exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/8\">",
"     8",
"    </a>",
"    ]. The pain is sometimes misconstrued as 'growth pain'. Although pain tends to diminish with age, it may be of sufficient severity to lead to suicide attempts.",
"   </p>",
"   <p>",
"    Electron microscopy of peripheral nerves reveals loss of small sensory neurons and lamellar inclusions consisting of glycosphingolipids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Nerve conduction studies are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pain relief",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of chronic neuropathic pain in patients with Fabry disease remains empiric [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/12\">",
"     12",
"    </a>",
"    ]. Preventive pain therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    appears to be beneficial.",
"   </p>",
"   <p>",
"    One potential advantage of anticonvulsants is that compliance may be monitored and the risk of toxicity reduced by following serum levels. However, these levels do not have a direct correlation with neuropathic pain response.",
"   </p>",
"   <p>",
"    Narcotic agents should be avoided if possible. Nonsteroidal antiinflammatory agents should also be avoided, as these tend to be ineffective and may lead to renal toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the anticonvulsants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is most often used [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Advantages of gabapentin include low toxicity, a low incidence of drug interactions, and lack of liver metabolism. The nearly complete renal clearance is potentially concerning in patients with Fabry disease, who are at risk for kidney disease. Therefore, renal function should be assessed before beginning gabapentin treatment and the dose should be adjusted accordingly, as renal function affects serum levels and half life.",
"   </p>",
"   <p>",
"    In children less than twelve years old the starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into three doses. The dose may be slowly increased up to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily. For older children and adults the initial dose is typically 300 mg three times a day (900 mg total a day). The maximum total dose may be in the range of 1800 to 2400 mg per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Other anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other anticonvulsants have been used for the treatment of neuropathic pain. Of the older drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    have been used most often [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, phenytoin is not commonly used for chronic treatment in children because of concerns about adverse cosmetic effects that include hirsutism, gingival hyperplasia and coarse facial features. In addition, chronic phenytoin treatment has been associated with the potential for cerebellar atrophy and peripheral neuropathy. Carbamazepine appears to be effective but causes induction of the P450 system in the liver, which can be a concern in patients on multiple drugs that are metabolized by the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Amitriptyline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     Amitriptyline",
"    </a>",
"    , at doses well below those used in the treatment of depression, has been shown to be effective in the treatment of chronic neuropathic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/17\">",
"     17",
"    </a>",
"    ]. At the lower doses used for neuropathic pain, serious side effects are uncommon. Nonetheless, an electrocardiogram should be obtained before and after beginning treatment since amitriptyline can cause adverse changes in cardiac conduction.",
"   </p>",
"   <p>",
"    The recommended starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    in children is 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at night. This can be slowly increased over two to four weeks up to 0.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    nightly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CEREBROVASCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral involvement in Fabry disease is due mainly to vasculopathy and a dilative arteriopathy in affected males and female carriers and may result in TIA, stroke, aneurysms, acute blindness, and accumulation of symptomatic and asymptomatic white matter lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. Cerebrovascular complications are rare in children, but increase through adult life.",
"   </p>",
"   <p>",
"    In data from 2446 patients in the observational Fabry Registry, the following results were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stroke affected 138 patients (5.6 percent), including 86 of 1243 males (6.9 percent) and 52 of 1203 females (4.3 percent). Most strokes were ischemic (87 percent).",
"     </li>",
"     <li>",
"      Median age at first stroke for males and females was 39 and 45.7 years, respectively.",
"     </li>",
"     <li>",
"      The proportion of patients with a first stroke prior to the diagnosis of Fabry disease in males and females was 50 and 38 percent, respectively. The proportion who experienced a stroke prior to renal or cardiac events for males and females was 71 and 77 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, stroke often occurs before the renal or cardiac manifestations of Fabry disease.",
"   </p>",
"   <p>",
"    In an earlier literature review, the average age of onset for cerebrovascular symptoms of Fabry disease was 34 years for hemizygotes (n = 43) and 40 years for heterozygotes (n = 10) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/20\">",
"     20",
"    </a>",
"    ]. The most frequent cerebrovascular manifestations in hemizygotes were hemiparesis, vertigo, dizziness, diplopia, dysarthria, nystagmus, nausea, vomiting, head pain, hemiataxia, and ataxia of gait. Heterozygotes were prone to memory loss, dizziness, ataxia, hemiparesis, loss of consciousness, and hemisensory symptoms. The most common angiographic and pathologic features were elongation, ectasia, and tortuosity involving the vertebral and basilar arteries.",
"   </p>",
"   <p>",
"    The cerebrovascular disease burden, in particular the white matter lesion load, increases with age. In an MRI study, lesions were present in no male patient under age 26 compared to all patients over age 54 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/24\">",
"     24",
"    </a>",
"    ]. Of the patients with white matter lesions, neurologic symptoms were present in 37.5 percent.",
"   </p>",
"   <p>",
"    White matter lesions also appear over time in female carriers. The Fabry Outcome Survey found that cerebrovascular events occurred in a high proportion of female and male patients (27 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The mean age of cerebrovascular event onset was below 30 in men and below 45 in women. In a subsequent case series of patients with symptomatic Fabry disease, the frequency of marked white matter lesions was similar among male and female patients (4 of 13 versus 5 of 14 [31 versus 36 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The explanation for the high burden of white matter lesions and cerebrovascular events in women with Fabry disease, an X-linked disorder, is unclear, as most female carriers do not have significant reductions in alpha-galactosidase enzyme activity. However, the observation has been made that Fabry disease can behave as a dominant rather than a recessive condition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Stroke prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard ischemic stroke prevention measures are considered effective in secondary (and possibly primary) prevention for patients with Fabry disease, although this conclusion is based solely upon clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, these measures include the use of antiplatelet agents (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    monotherapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    monotherapy, or the combination of aspirin with extended-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ), antihypertensive agents and statins. These treatments are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy is suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27063?source=see_link\">",
"     \"Ischemic stroke in children: Secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The limited evidence regarding the impact of enzyme replacement therapy on stroke incidence in Fabry disease is summarized in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENZYME REPLACEMENT AND NEUROLOGIC OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no cure for Fabry disease, the available data suggest that enzyme replacement therapy (either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38867?source=see_link\">",
"     agalsidase alfa",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/34/8741?source=see_link\">",
"     agalsidase beta",
"    </a>",
"    ) may reduce the severity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of disease manifestations, as discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=see_link\">",
"     \"Treatment of Fabry disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are summaries of the effects of enzyme replacement therapy on short-term neurologic complications in the phase",
"    <span class=\"nowrap\">",
"     II/III",
"    </span>",
"    clinical trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The NIH trial involved 26 hemizygous males treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38867?source=see_link\">",
"       agalsidase alfa",
"      </a>",
"      (0.2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      infusion or placebo, which was administered every two weeks for 12 doses (24 weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/30\">",
"       30",
"      </a>",
"      ]. Active treatment significantly decreased plasma and urine Gb3 levels. The primary outcome measure, neuropathic pain assessed by questionnaire, was significantly improved with active treatment, but not placebo.",
"     </li>",
"     <li>",
"      In the International Fabry Disease Study, 58 patients (including 2 females) were randomly assigned to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/34/8741?source=see_link\">",
"       agalsidase beta",
"      </a>",
"      or placebo administered every two weeks for 20 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/31\">",
"       31",
"      </a>",
"      ]. The primary end point (fraction of patients free of microvascular endothelial deposits of Gb3 in the kidney), was realized in 69 and zero percent in the active and placebo groups, respectively. The fraction of patients with reduced pain, on the other hand, was similar in both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reports of long-term neurologic outcomes following enzyme replacement therapy are limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One open-label extension study of the International Fabry Disease Study Group treated 58 patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/34/8741?source=see_link\">",
"       agalsidase beta",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every two weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/32\">",
"       32",
"      </a>",
"      ]. After 30 months (original placebo group) or 36 months (original treatment group) of enzyme replacement therapy, pain scores, as assessed by the McGill questionnaire, remained low in all patients. Stroke or TIA occurred in 5 of 58 patients (8.6 percent), one of whom had a prior history of stroke. There was no comparison control group, but the historic rate of stroke in the Genzyme data on file as reported by the authors was 13.7 percent.",
"     </li>",
"     <li>",
"      Another open-label extension study included 25 adult men with Fabry disease who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38867?source=see_link\">",
"       agalsidase alfa",
"      </a>",
"      (0.2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      every other week [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/33\">",
"       33",
"      </a>",
"      ]. Stroke was not a prespecified outcome measure. However, during the 4 to 4.5 years of the study while on enzyme replacement therapy, four patients (16 percent) had a stroke or TIA.",
"     </li>",
"     <li>",
"      The Fabry Outcome Survey included 545 patients from 11 European countries, of whom 314 had received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38867?source=see_link\">",
"       agalsidase alfa",
"      </a>",
"      for at least one (60 percent) or two (29 percent) years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/34\">",
"       34",
"      </a>",
"      ]. Measures of pain and interference of pain with daily activities were variably improved at one and two years. There was a sustained improvement in quality of life at one and two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the available data suggest that enzyme replacement therapy for Fabry disease decreases neuropathic pain, but does not appreciably reduce the incidence of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27414/abstract/29,35\">",
"     29,35",
"    </a>",
"    ]. Larger long-term studies are needed to determine whether enzyme replacement therapy will reduce the risk of stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90490110\">",
"    <span class=\"h1\">",
"     REGISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Fabry disease registry has been established to better understand the variability and progression of the disease. Information is available online at",
"    <a class=\"external\" href=\"file://www.lsdregistry.net/fabryregistry/\">",
"     www.lsdregistry.net/fabryregistry/",
"    </a>",
"    and by telephone at 800-745-4447 x15500 in the United States and +31-35-699-1232 in Europe. Participation in the registry is voluntary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90489997\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral neuropathy associated with Fabry disease causes an almost constant discomfort with paroxysmal burning pains of the hands and feet. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Peripheral neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic therapy for neuropathic pain with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      may provide relief. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pain relief'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cerebral involvement in Fabry disease is due mainly to vasculopathy and a dilative arteriopathy in affected males and female carriers and may result in TIA, stroke, aneurysms, acute blindness, and accumulation of symptomatic and asymptomatic white matter lesions. Cerebrovascular complications are rare in children, but increase through adult life. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cerebrovascular complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For secondary prevention of ischemic stroke in adults with Fabry disease, we recommend the use of antiplatelet agents, antihypertensive agents and statins. For children, only antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is suggested. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Stroke prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enzyme replacement therapy is recommended for classically affected males with Fabry disease (ie, males with very low or undetectable levels of alpha-galactosidase A) who are symptomatic; enzyme replacement therapy is suggested for classically affected males with Fabry disease who are asymptomatic, as reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=see_link\">",
"       \"Treatment of Fabry disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In terms of neurologic manifestations, the available data suggest that enzyme replacement therapy for Fabry disease decreases neuropathic pain, but does",
"      <strong>",
"       not",
"      </strong>",
"      appreciably reduce the incidence of stroke. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Enzyme replacement and neurologic outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/1\">",
"      Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276:1163.",
"     </a>",
"    </li>",
"    <li>",
"     Desnick, RJ, Sweeley, CC. Fabry's disease: Alpha-galactosidase A deficiency. In: Peripheral Neuropathy, vol 2, Stanbury JB, Wyngaarden, JB, Fredrickson, DS, Goldstein, JL (Eds), McGraw Hill, New York 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/3\">",
"      Eng CM, Desnick RJ. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum Mutat 1994; 3:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/4\">",
"      Eng CM, Ashley GA, Burgert TS, et al. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 1997; 3:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/5\">",
"      Topaloglu AK, Ashley GA, Tong B, et al. Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol Med 1999; 5:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/6\">",
"      von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991; 324:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/7\">",
"      Toyooka K. Fabry disease. Curr Opin Neurol 2011; 24:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/8\">",
"      Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004; 144:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/9\">",
"      Vital A, Vital C, Maleville J. Fabry's disease: an ultrastructural study of muscle and peripheral nerve. Clin Neuropathol 1984; 3:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/10\">",
"      Onishi A, Dyck PJ. Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns. Arch Neurol 1974; 31:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/11\">",
"      Scott LJ, Griffin JW, Luciano C, et al. Quantitative analysis of epidermal innervation in Fabry disease. Neurology 1999; 52:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/12\">",
"      MacDermot J, MacDermot KD. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001; 429:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/13\">",
"      Germain DP. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations]. J Soc Biol 2002; 196:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/14\">",
"      Ries M, Mengel E, Kutschke G, et al. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 2003; 26:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/15\">",
"      Lockman LA, Hunninghake DB, Krivit W, Desnick RJ. Relief of pain of Fabry's disease by diphenylhydantoin. Neurology 1973; 23:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/16\">",
"      Lenoir G, Rivron M, Gubler MC, et al. [Fabry's disease. Carbamazepine therapy in acrodyniform syndrome]. Arch Fr Pediatr 1977; 34:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/17\">",
"      Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005; :CD005454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/18\">",
"      Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol 1979; 97:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/19\">",
"      Maisey DN, Cosh JA. Basilar artery aneurysm and Anderson-Fabry disease. J Neurol Neurosurg Psychiatry 1980; 43:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/20\">",
"      Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996; 40:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/21\">",
"      Garzuly F, Mar&oacute;di L, Erd&ouml;s M, et al. Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene. Brain 2005; 128:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/22\">",
"      Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 2008; 79:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/23\">",
"      Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009; 40:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/24\">",
"      Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998; 50:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/25\">",
"      MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/26\">",
"      Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/27\">",
"      Fellgiebel A, M&uuml;ller MJ, Mazanek M, et al. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005; 65:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/28\">",
"      Percy AK, Kaye EM. Does gender parity exist in Fabry disease? Neurology 2005; 65:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/29\">",
"      Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007; 257:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/30\">",
"      Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/31\">",
"      Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med 2001; 345:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/32\">",
"      Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/33\">",
"      Schiffmann R, Ries M, Timmons M, et al. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006; 21:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/34\">",
"      Beck M, Ricci R, Widmer U, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004; 34:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27414/abstract/35\">",
"      El Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2013; 2:CD006663.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6194 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-57BF54AE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27414=[""].join("\n");
var outline_f26_49_27414=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H90489997\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERIPHERAL NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pain relief",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Other anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Amitriptyline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CEREBROVASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Stroke prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENZYME REPLACEMENT AND NEUROLOGIC OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90490110\">",
"      REGISTRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90489997\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6194\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6194|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/27/37308\" title=\"table 1\">",
"      Lysosomal storage disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=related_link\">",
"      Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=related_link\">",
"      Clinical features and diagnosis of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27063?source=related_link\">",
"      Ischemic stroke in children: Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=related_link\">",
"      Treatment of Fabry disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_49_27415="Ventricular couplet tutorial";
var content_f26_49_27415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1093px;\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Ventricular couplet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 98px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two ventricular premature beats (VPBs) occur following three normal QRS complexes. This is a unifocal couplet since both VPBs have the same morphology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27415=[""].join("\n");
var outline_f26_49_27415=null;
var title_f26_49_27416="Pharmacotherapy for social anxiety disorder";
var content_f26_49_27416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacotherapy for social anxiety disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27416/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27416/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27416/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27416/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27416/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27416/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/49/27416/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13589961\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social anxiety disorder (SAD), also known as social phobia, is a condition marked by extreme fear of situations that involve possible scrutiny by others. The individual is concerned that embarrassment or humiliation will result, and so he or she avoids such situations, or endures them with intense anxiety.",
"   </p>",
"   <p>",
"    SAD is a prevalent condition, estimated to affect between 4 and 10 percent of the adult United States population over a 12 month period. SAD typically begins in childhood or adolescence and, untreated, can be associated with the subsequent development of major depression, substance abuse, and other mental health problems. The disorder can be associated with extensive functional impairment and reduced quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic addresses the pharmacological treatment of SAD. Discussed separately are epidemiology, pathogenesis, clinical manifestations, and diagnosis of SAD; psychotherapy for SAD; and fears and specific phobias in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=see_link\">",
"     \"Psychotherapy for social anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=see_link\">",
"     \"Overview of fears and specific phobias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H283170756\">",
"    <span class=\"h1\">",
"     SUBTYPES OF SOCIAL ANXIETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social anxiety disorder (SAD) has two clinical subtypes, generalized and nongeneralized.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In generalized SAD, distressing fears are experienced in multiple social situations that typically include social interactional situations (eg, engaging in a conversation, meeting new people, attending parties, relating to co-workers and bosses).",
"     </li>",
"     <li>",
"      In nongeneralized or circumscribed SAD, fears are limited to one or a few social situations, which tend to be social performance (rather than interactional) situations (eg, public speaking; writing in front of others).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13589968\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several classes of drugs are used to treat SAD, including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), beta-blockers, and benzodiazepines. Pharmacologic treatment is quite different for generalized versus nongeneralized SAD.",
"   </p>",
"   <p>",
"    We suggest SSRIs or SNRIs be used as first-line medication treatment for generalized SAD based on a combination of efficacy, tolerability, and safety. We suggest beta-blockers or benzodiazepines as first-line medication treatment for nongeneralized SAD (most commonly performance anxiety). (See",
"    <a class=\"local\" href=\"#H13589975\">",
"     'Generalized social anxiety disorder'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13590038\">",
"     'Nongeneralized social anxiety disorder'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    SSRIs, SNRIs, and MAOIs all require four to six weeks to achieve an effect, and up to 16 weeks to achieve full effect. They need to be taken on a regular, daily basis. Beta-blockers and benzodiazepines achieve their effects within 30 to 60 minutes, and are used on an \"as needed\" basis for non-generalized SAD. Long-acting benzodiazepines may also be used on a regular (not &ldquo;as needed&rdquo;) basis for generalized SAD, as discussed below.",
"   </p>",
"   <p>",
"    Based on findings from numerous clinical trials, approximately one-half of patients with SAD show significant clinical improvement in response to current treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. There are no consistently proven predictors of response to pharmacotherapy in general, or to specific medications.",
"   </p>",
"   <p>",
"    We suggest that treatment with SSRIs, SNRIs, or MAOIs be continued for at least 6 to 12 months to prevent relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13589975\">",
"    <span class=\"h2\">",
"     Generalized social anxiety disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical trials of SAD in the past decade have evaluated treatments for the generalized subtype of the disorder or do not specify the subtype of patients enrolled in the study. These trials, using regular daily dosing of medication, are described in this section. \"As needed\" dosing for situational or nongeneralized SAD is discussed separately. (See",
"    <a class=\"local\" href=\"#H13590038\">",
"     'Nongeneralized social anxiety disorder'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Whenever pharmacotherapy is prescribed for generalized SAD, it is good clinical practice to recommend to the patient that he or she enter previously feared social situations to &ldquo;test out&rdquo; the effects of the medication and to learn that these situations are safe and can be tolerated. Although there are no research data to support this claim, there is some reason to believe that those patients who do the most &ldquo;practicing&rdquo; and &ldquo;expanding of their social horizons&rdquo; while on medication are the ones who have the best longer-term outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13589982\">",
"    <span class=\"h3\">",
"     Selective serotonin reuptake inhibitors (SSRIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRIs are the best studied and the most commonly prescribed of the medication treatments for SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/2\">",
"     2",
"    </a>",
"    ]. The SSRI",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    was the first medication to receive US FDA approval for SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/6\">",
"     6",
"    </a>",
"    ], and numerous subsequent studies have gone on to confirm efficacy for this and other SSRIs.",
"   </p>",
"   <p>",
"    A meta-analysis of seven trials compared SSRIs to placebo in a total of 896 patients with SAD. SSRIs resulted in greater symptom reduction and had a moderate effect size [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, 183 patients with SAD were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (20 to 50 mg) or placebo for 11 weeks. Patients receiving paroxetine (55 percent) were more likely to be &ldquo;much improved&rdquo; or &ldquo;very much improved&rdquo; at the end of treatment compared to patients on placebo (24 percent). The mean score on the Liebowitz Social Anxiety Scale was reduced by 39 percent in the paroxetine group, compared to 17 percent in the placebo group.",
"   </p>",
"   <p>",
"    The clinical effects of SSRI treatment for SAD typically require four to six weeks to have a significant impact; maximal benefit can require as long as 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients should be encouraged to &ldquo;try out&rdquo; the medication by engaging in social situations that typically result in anxiety and to report back about their response. One of the first indications of response is the patient&rsquo;s report of feeling less &ldquo;self-conscious&rdquo; in typical social situations. Higher doses of SSRI typically result in better outcomes, so the dose is usually pushed to the maximum tolerated by the individual (unless an excellent response is attained at a lower dose, at which point the dose would be held there to ascertain stability of the response).",
"   </p>",
"   <p>",
"    Although some SSRIs have been more extensively studied than others in the treatment of SAD, there is no evidence of superiority of one SSRI over another. As examples,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    can be started at 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    taken orally and, if the patient does not respond after 6 weeks, can be increased in 10 mg increments every few weeks to a maximum of 60",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     Sertraline",
"    </a>",
"    can be started at 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    taken orally and, if the patients does not respond after 6 weeks, can be increased in 50 mg every few weeks to a maximum of 250",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Common side effects of SSRIs include restlessness, agitation, headache, diarrhea, nausea and insomnia. SSRIs also cause sexual dysfunction in as many as 50 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=see_link\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of the side effects can be reduced or avoided by starting the medication at lower doses and increasing it gradually. See table for standard and lower initial doses as well as the range of therapeutic doses for SSRIs (",
"    <a class=\"graphic graphic_table graphicRef81315 \" href=\"UTD.htm?27/31/28157\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13589989\">",
"    <span class=\"h3\">",
"     Serotonin norepinephrine reuptake inhibitors (SNRIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less well studied than the SSRIs, the serotonin norepinephrine reuptake inhibitor (SNRI)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    extended release is an equally effective treatment for SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One trial randomly assigned 440 patients with SAD to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    (75 to 225 mg daily extended release),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (20 to 50 mg daily), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/8\">",
"     8",
"    </a>",
"    ]. After 12 weeks, response rates were similar in the venlafaxine and paroxetine groups, both of which were superior to placebo (59 and 63 versus 36 percent response, respectively). Medication discontinuation rates were similar with venlafaxine and paroxetine, but adverse events leading to a reduction in dosage were more common with venlafaxine (16 versus 8 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    can be started at 37.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    taken orally and increased to a dose within the therapeutic range, between 75 and 225",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef81315 \" href=\"UTD.htm?27/31/28157\">",
"     table 1",
"    </a>",
"    ). SSRI recommendations regarding gradual titration, trial duration, and dose increases apply to SNRIs as well.",
"   </p>",
"   <p>",
"    The most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    are nausea, dizziness, insomnia, sedation and constipation. Venlafaxine may cause elevations in blood pressure. Though usually small, the increases can be significant in some patients. The medication should be avoided in patients with hypertension, and blood pressure should be monitored during use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no published data from controlled trials on the use of another marketed SNRI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , in the treatment of SAD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13589996\">",
"    <span class=\"h3\">",
"     Monoamine oxidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The monoamine oxidase inhibitors (MAOIs) have the longest track record of use for SAD, having been essentially the only pharmacotherapy available (though never FDA approved) for SAD prior to the advent of the SSRIs. However, side effects and dietary restrictions limit their use. MAOIs are generally reserved for SAD refractory to other treatments. Some practitioners feel that MAOIs are more effective than SSRIs or SNRIs, though no comparative efficacy trials have been conducted to substantiate this belief. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several randomized trials have found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    is an efficacious treatment for SAD, with approximately one-half of patients responding with a clinically significant reduction in symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/7\">",
"     7",
"    </a>",
"    ]. A recent randomized trial that included a phenelzine arm found a response rate of 54 percent for phenelzine compared to 33 percent for placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/11\">",
"     11",
"    </a>",
"    ]. Phenelzine is typically started at 15 mg once or twice daily, and increased to a total dose of 60 to 90",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    based on response. It can take four to six weeks for a response to occur, and longer for maximal response to be attained.",
"   </p>",
"   <p>",
"    MAOIs cause inhibition of the MAO enzyme. Irreversible MAOIs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    , are incompatible with certain foods and medications (eg, cheese, aged meats, alcohol, OTC cold preparations). A potentially fatal hypertensive reaction can occur if users of MAOIs consume food containing tyramine; thus, use of irreversible MAOIs must be accompanied by a low tyramine diet. Their use is also contraindicated with other antidepressants, and over-the-counter or prescribed medications containing sympathomimetic stimulants or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Other adverse effects common at therapeutic doses include postural hypotension, insomnia, paradoxical daytime sedation, sexual dysfunction, and weight gain. In many instances, these side effects can be dose limiting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590003\">",
"    <span class=\"h3\">",
"     Reversible inhibitors of monoamine type A",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/5/18518?source=see_link\">",
"     Moclobemide",
"    </a>",
"    , a reversible MAOI selective for inhibition of MAO-A has shown, at best, mixed results in randomized controlled trials of SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Moclobemide is not marketed in the United States, but is available in many other countries. In contrast to non-reversible MAOIs (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"     tranylcypromine",
"    </a>",
"    ), moclobemide does not require a low tyramine diet, and generally has fewer adverse effects overall. Although it had been hoped by practitioners that moclobemide would be as efficacious as MAOIs, its efficacy seems to be no better (perhaps even less) than that of SSRIs or SNRIs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590010\">",
"    <span class=\"h3\">",
"     Beta adrenergic blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-blockers are not an effective treatment for generalized SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], but are effective for nongeneralized SAD (including performance anxiety). (See",
"    <a class=\"local\" href=\"#H13590038\">",
"     'Nongeneralized social anxiety disorder'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590017\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only two, small randomized controlled trials have been published, which found the high potency benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/17\">",
"     17",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/18\">",
"     18",
"    </a>",
"    ], to be efficacious as monotherapy in the reduction of SAD symptoms. Another study found modest evidence of superiority of an SSRI plus clonazepam compared to SSRI alone in the treatment of generalized SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sedation and the potential for abuse and dependence limit the usefulness of these agents. Benzodiazepines should generally be avoided in patients with a history of alcohol or other substance abuse; though judicious prescription of benzodiazepines can be undertaken in such patients when other treatments are ineffective.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    , a longer-acting agent with a slower rate of onset, seems to be more commonly used for generalized SAD than other benzodiazepines. Sedation, the principal dose-limiting adverse effect, can be minimized by starting with low doses and titrating upwards slowly until a satisfactory response is achieved. Clonazepam can be started at 0.25 to 0.50 mg twice daily, to a maximum of 2 mg twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590024\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    (an anticonvulsant) and the related compound",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    (marketed for certain types of neuropathic pain and for fibromyalgia), have demonstrated modest effectiveness (response rates &lt;45 percent) for generalized SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The role of these compounds in the treatment of SAD is unclear, but some practitioners will consider using either of them as monotherapy (in cases where a benzodiazepine is desired, but the patient has a substance abuse history) or, more commonly, as an adjunct to an SSRI or SNRI. Doses of gabapentin for SAD typically range from 900 mg to 3600 mg daily in three divided doses. Doses of pregabalin for SAD typically range from 150 to 600 mg per day.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    (30 mg a day) was found to be efficacious for SAD in a randomized control trial of 66 women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/22\">",
"     22",
"    </a>",
"    ]. In a more recent randomized controlled trial of 60 men and women with generalized SAD randomized to either 30 to 45",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (n= 30) or placebo (n= 30) for 12 weeks, mirtazapine was no more effective than placebo (13 percent versus 13 percent response rate).",
"   </p>",
"   <p>",
"    The tricyclic antidepressants (TCAs) have not been well studied in clinical trials of patients with SAD. A small open-label trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    suggested that it was not effective. It is possible that TCAs with more potent serotonergic reuptake blockade (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    ) might be useful, but this is unknown.",
"   </p>",
"   <p>",
"    Very small randomized controlled trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    suggested that these atypical (or &ldquo;second-generation&rdquo;) antipsychotics might be effective for SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Considerable further study is needed as well as consideration of metabolic side effects of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limited available data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    is ineffective as monotherapy for SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    , a selective norepinephrine reuptake inhibitor (marketed for the treatment of attention deficit",
"    <span class=\"nowrap\">",
"     disorder/hyperactivity)",
"    </span>",
"    was not shown to be effective for generalized SAD in a small randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/27\">",
"     27",
"    </a>",
"    ]. However, there is some evidence from a trial in adults with comorbid ADHD and SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/28\">",
"     28",
"    </a>",
"    ] that atomoxetine may be helpful for both ADHD and SAD symptoms in patients who have both .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590031\">",
"    <span class=\"h3\">",
"     Pharmacotherapy augmentation or switching",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial number of patients respond only partially to monotherapy for generalized SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/2\">",
"     2",
"    </a>",
"    ], this has generated interest in strategies that combine SSRIs (or SNRIs) with other agents. Small trials yielded positive results augmenting SSRIs with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/29\">",
"     29",
"    </a>",
"    ], but equivocal results from augmentation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/19\">",
"     19",
"    </a>",
"    ] or and negative results from augmentation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/30\">",
"     30",
"    </a>",
"    ]. MAOIs should not be combined with other antidepressants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no available data on whether switching from one SSRI to another, or from an SSRI to an SNRI, is useful in the treatment of non-responders to initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590038\">",
"    <span class=\"h2\">",
"     Nongeneralized social anxiety disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;In nongeneralized or circumscribed SAD, symptoms are limited to specific performances or circumstances, and are often described as &ldquo;performance anxiety&rdquo;. For this reason, medication treatment is often prescribed on an \"as needed\" basis. We suggest benzodiazepines or beta-blockers as first-line medication treatment. Administering a test dose prior to treatment can be useful to assess the drug's effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590052\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines can also be used on an \"as needed\" basis to treat nongeneralized SAD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    0.25 to 1 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.5 to 2 mg can be given 30 to 60 minutes before the performance. Tolerance and physical dependence are not a concern with occasional use. But the potential for abuse, highest in persons with a history of alcohol or other substance use, should also limit their use in this context.",
"   </p>",
"   <p>",
"    Sedation can be a side effect of benzodiazepines, particularly at higher doses. For this reason, the patient should be encouraged to try out the medication in advance of a potentially precipitating event to determine how well it is tolerated and to see if it is efficacious. The prescribing physician may need to fine-tune the dose for the individual. Patients may have used alcohol in the past to cope with similar situations and should be explicitly cautioned not to mix alcohol with benzodiazepines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589024\">",
"    <span class=\"h3\">",
"     Beta-adrenergic blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small trials have found beta-blockers to reduce performance anxiety (including public speaking). However, these studies were conducted with normal or anxious volunteers rather than individuals diagnosed with SAD. Beta-adrenergic blockers may be most useful for patients who have prominent awareness of physiological symptoms such as tachycardia or tremor.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    can be taken orally 30 to 60 minutes prior to the anxiety-inducing situation, at a dose of 20 to 60 mg. The patient should be encouraged to try out the medication in advance of a potentially precipitating event to determine how well it is tolerated and to see if it is efficacious. The prescribing physician may need to fine-tune the dose for the individual. Contraindications to the prescription of beta-blockers include: a history of beta-blocker intolerance or allergy, asthma, diabetes, and certain cardiac conditions (eg, conduction problems). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590059\">",
"    <span class=\"h1\">",
"     COMBINED PSYCHOLOGICAL AND PHARMACOLOGICAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345381276\">",
"    <span class=\"h2\">",
"     CBT and antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have assessed clinical interventions combining antidepressant medication and CBT for generalized SAD, but evidence of an additive effect for combining the two modalities is mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/11,29,31\">",
"     11,29,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 128 patients with generalized SAD found group CBT and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"       phenelzine",
"      </a>",
"      was more effective than either intervention individually or pill placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/11\">",
"       11",
"      </a>",
"      ]. The combination of CBT and phenelzine resulted in a higher response rate (71.9 percent) than placebo (33.3 percent), CBT alone (47.1 percent), or phenelzine alone (54.3 percent).",
"     </li>",
"     <li>",
"      In a trial of 295 patients with generalized SAD, patients were randomized to one of five groups:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , group CBT, combined group CBT and placebo, combined group CBT and fluoxetine, or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/31\">",
"       31",
"      </a>",
"      ]. A higher proportion of patients responded to fluoxetine (51 percent), group CBT (52 percent), combined group CBT and placebo (51 percent) and combined group CBT and fluoxetine (54 percent) than to placebo (32 percent). However, the group receiving combined medication and CBT did not differ significantly in response compared to groups receiving either monotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    and exposure therapy did not show greater effectiveness than either modality individually in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362076425\">",
"    <span class=\"h2\">",
"     CBT and d-cycloserine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small randomized trials have found that d-cycloserine, a partial N-methyl-d-aspartate (NMDA) receptor agonist believed to enhance certain kinds of learning, enhanced the efficacy of CBT for SAD when the medication was provided prior to the exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. It is unclear if the effect of d-cycloserine is to &ldquo;accelerate&rdquo; response to CBT, thereby requiring fewer CBT sessions to achieve a response, or whether it can truly &ldquo;augment&rdquo; response, yielding a superior overall response rate than CBT alone. The use of d-cycloserine to augment CBT is still experimental, and cannot be recommended at present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590066\">",
"    <span class=\"h1\">",
"     TREATMENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no empirically-derived algorithms for treating SAD. Based on available data and clinical experience, we approach the disorder as follows.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362076946\">",
"    <span class=\"h2\">",
"     Generalized social anxiety disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend either pharmacotherapy or CBT for initial treatment of SAD. Both treatments reduce social anxiety compared to placebo. The selection between pharmacotherapy and CBT should be made on the basis of informed patient preference and treatment availability. Randomized trials comparing CBT to pharmacotherapy for SAD have not demonstrated superiority of one treatment over the other [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/11,29,31\">",
"     11,29,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H345381276\">",
"     'CBT and antidepressants'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Onset of symptom response may be faster with pharmacotherapy, although CBT appears to result in a more durable response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27416/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If medication is chosen for first-line treatment for generalized SAD, we suggest use of an SSRI or an SNRI. (See",
"    <a class=\"local\" href=\"#H13589982\">",
"     'Selective serotonin reuptake inhibitors (SSRIs)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13589989\">",
"     'Serotonin norepinephrine reuptake inhibitors (SNRIs)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If only a partial response is achieved from an SSRI or CBT, the addition of the other modality in a &ldquo;stepped care&rdquo; approach may be helpful, although this has not been adequately studied. If pharmacotherapy has been selected and an SSRI has not led to an adequate response after 12 weeks, an SNRI can be used (or vice-versa).",
"   </p>",
"   <p>",
"    With appropriate precautions (ie, restrictions on diet and certain medications), an irreversible MAOI such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    can be used to treat generalized SAD that has been refractory to treatment with other medications. The MAOI should be used in place of the previous antidepressant, not in conjunction with it. The prior antidepressant should be stopped at least two weeks before beginning an MAOI to avoid precipitating a hypertensive reaction or serotonin syndrome. This wash out would be longer, up to five weeks, for antidepressants that have a longer half life, eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H13589996\">",
"     'Monoamine oxidase inhibitors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362076966\">",
"    <span class=\"h2\">",
"     Nongeneralized social anxiety disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest treating SAD that is restricted to only a performance or another discrete circumstance with either CBT or a medication. CBT would be most useful when the feared situation will be regularly encountered by the individual, while an &ldquo;as needed&rdquo; dose of medication is better suited to situations that are only rarely or occasionally encountered, or where the patient prefers medication or where CBT is not available.",
"   </p>",
"   <p>",
"    When treating nongeneralized SAD with medication, we suggest treatment with a benzodiazepine for patients who lack a history of a substance use disorder and do not experience sedation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    (0.25 to 1 mg) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (0.5 to 2 mg) can be given 30 to 60 minutes before a performance. For patients without contraindications to their use, treatment with a beta-blocker is a reasonable alternative.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    (20 to 60 mg) can be given 30 to 60 minutes before the anxiety-inducing situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/42/20129?source=see_link\">",
"       \"Patient information: Social anxiety disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590089\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Social anxiety disorder (SAD), also known as social phobia, is characterized by an individual's unreasonable fear of embarrassment in social or performance situations, which he or she either avoids or experiences with intense anxiety. (See",
"      <a class=\"local\" href=\"#H13589961\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H283170756\">",
"       'Subtypes of social anxiety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In generalized SAD, distressing fears are experienced in multiple social situations that typically include social interaction.",
"     </li>",
"     <li>",
"      In nongeneralized or circumscribed SAD, fears are limited to one or a few social situations, which tend to be performance rather than interactional situations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590073\">",
"    <span class=\"h2\">",
"     Generalized social anxiety disorder",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whenever pharmacotherapy is prescribed for generalized SAD, it is good clinical practice to recommend to the patient that he enter previously feared social situations to &ldquo;test out&rdquo; the effects of the medication and to learn that these situations are safe and can be tolerated. (See",
"      <a class=\"local\" href=\"#H13589975\">",
"       'Generalized social anxiety disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend first-line treatment of patients with generalized SAD with an antidepressant or cognitive behavioral therapy (CBT) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      )",
"      <strong>",
"       .",
"      </strong>",
"      Selection between them can be made on the basis of informed patient preference and treatment availability. (See",
"      <a class=\"local\" href=\"#H13590066\">",
"       'Treatment selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When pharmacotherapy is preferred, we suggest selective serotonin reuptake inhibitors (SSRIs) or SNRIs for first-line medication treatment of generalized SAD (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       Paroxetine",
"      </a>",
"      , an SSRI, can be started at 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      taken orally and, if the patient does not respond after 6 weeks, can be increased to a maximum of 60",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      &nbsp;(See",
"      <a class=\"local\" href=\"#H13589982\">",
"       'Selective serotonin reuptake inhibitors (SSRIs)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       Venlafaxine",
"      </a>",
"      , an SNRI, can be started at 37.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      taken orally and increased to a dose within the therapeutic range (between 75 and 225",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H13589989\">",
"       'Serotonin norepinephrine reuptake inhibitors (SNRIs)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other agents with some (but considerably less) support for efficacy in SAD include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SSRIs, SNRIs, and MAOIs may take four to six weeks for an initial response and 12 to 16 weeks to achieve their full effect. These or other medications for generalized SAD should be continued for at least 6 to 12 months to decrease the likelihood of relapse. Some patients may need continuing treatment to maintain the gains achieved. (See",
"      <a class=\"local\" href=\"#H13589968\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13590081\">",
"    <span class=\"h2\">",
"     Nongeneralized social anxiety disorder",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest treating SAD that is restricted to a performance or another discrete circumstance, which is rarely or only occasionally encountered, with medication rather than psychotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13590038\">",
"       'Nongeneralized social anxiety disorder'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who lack a history of a substance use disorder and do not experience sedation, we suggest treatment with a benzodiazepine. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       Clonazepam",
"      </a>",
"      (0.25 to 1 mg) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      (0.5 to 2 mg) can be given 30 to 60 minutes before a performance. &nbsp;(See",
"      <a class=\"local\" href=\"#H13590052\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without contraindications to their use, a beta-blocker is a reasonable alternative.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      (20 to 60 mg) can be given 30 to 60 minutes before the anxiety-inducing situation. (See",
"      <a class=\"local\" href=\"#H589024\">",
"       'Beta-adrenergic blockers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest treating SAD that is restricted to a performance or another discrete circumstance, which would be encountered more regularly, with cognitive behavioral therapy (CBT) rather than medication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); however, this choice can reasonably be made on the basis of treatment availability or patient preference. (See",
"      <a class=\"local\" href=\"#H362076966\">",
"       'Nongeneralized social anxiety disorder'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=see_link\">",
"       \"Psychotherapy for social anxiety disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/1\">",
"      Ruscio AM, Brown TA, Chiu WT, et al. Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med 2008; 38:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/2\">",
"      Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010; 71:839.",
"     </a>",
"    </li>",
"    <li>",
"     Ravindran LN, Stein MB. Anxiety Disorders: Somatic Treatment. In: Kaplan and Sadock Comprehensive Textbook of Psychiatry, 9th ed, Sadock BJ, Sadock VA, Ruiz P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, PA 2009. p.1906.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/4\">",
"      Schneier FR. Clinical practice. Social anxiety disorder. N Engl J Med 2006; 355:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/5\">",
"      Stein MB, Stein DJ. Social anxiety disorder. Lancet 2008; 371:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/6\">",
"      Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/7\">",
"      Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social phobia. Cochrane Database Syst Rev 2004; :CD001206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/8\">",
"      Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005; 62:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/9\">",
"      Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005; 66:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/10\">",
"      Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005; 177:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/11\">",
"      Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010; 67:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/12\">",
"      The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997; 247:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/13\">",
"      Schneier FR, Goetz D, Campeas R, et al. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/14\">",
"      Noyes R Jr, Moroz G, Davidson JR, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997; 17:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/15\">",
"      Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992; 49:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/16\">",
"      Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994; 62:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/17\">",
"      Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991; 48:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/18\">",
"      Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/19\">",
"      Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004; 65:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/20\">",
"      Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/21\">",
"      Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004; 24:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/22\">",
"      Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/23\">",
"      Vaishnavi S, Alamy S, Zhang W, et al. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/24\">",
"      Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/25\">",
"      Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010; :CD008120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/26\">",
"      van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997; 58:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/27\">",
"      Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 2009; 29:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/28\">",
"      Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009; 26:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/29\">",
"      Blomhoff S, Haug TT, Hellstr&ouml;m K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001; 179:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/30\">",
"      Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/31\">",
"      Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004; 61:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/32\">",
"      Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27416/abstract/33\">",
"      Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63:298.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 505 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27416=[""].join("\n");
var outline_f26_49_27416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13590089\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13589961\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H283170756\">",
"      SUBTYPES OF SOCIAL ANXIETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13589968\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13589975\">",
"      Generalized social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13589982\">",
"      - Selective serotonin reuptake inhibitors (SSRIs)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13589989\">",
"      - Serotonin norepinephrine reuptake inhibitors (SNRIs)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13589996\">",
"      - Monoamine oxidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13590003\">",
"      - Reversible inhibitors of monoamine type A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13590010\">",
"      - Beta adrenergic blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13590017\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13590024\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13590031\">",
"      - Pharmacotherapy augmentation or switching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13590038\">",
"      Nongeneralized social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13590052\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H589024\">",
"      - Beta-adrenergic blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13590059\">",
"      COMBINED PSYCHOLOGICAL AND PHARMACOLOGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H345381276\">",
"      CBT and antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362076425\">",
"      CBT and d-cycloserine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13590066\">",
"      TREATMENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362076946\">",
"      Generalized social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362076966\">",
"      Nongeneralized social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13590089\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13590073\">",
"      Generalized social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13590081\">",
"      Nongeneralized social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/505\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/505|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/31/28157\" title=\"table 1\">",
"      SSRI and SNRI meds",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=related_link\">",
"      Overview of fears and specific phobias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/42/20129?source=related_link\">",
"      Patient information: Social anxiety disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=related_link\">",
"      Psychotherapy for social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=related_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_49_27417="Methotrexate treatment of tubal and interstitial ectopic pregnancy";
var content_f26_49_27417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Methotrexate treatment of tubal and interstitial ectopic pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27417/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27417/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27417/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27417/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27417/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/49/27417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic pregnancy is a potentially life-threatening condition. While surgical approaches are the mainstay of treatment, advances in early diagnosis facilitated the introduction of medical therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) in the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/1\">",
"     1",
"    </a>",
"    ]. In one report, approximately 35 percent of women with ectopic pregnancy are eligible for medical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/2\">",
"     2",
"    </a>",
"    ]. Due to the routine use of early ultrasound among infertile patients who conceive, diagnosis of ectopic pregnancy can be established early and medical treatment can be administered in most cases. The overall success rate of medical treatment in properly selected women is nearly 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical treatment of ectopic pregnancy will be reviewed here. Ectopic pregnancy diagnosis, surgical treatment and expectant management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=see_link\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21444?source=see_link\">",
"     \"Expectant management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX is a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    antagonist widely used for treatment of neoplasia, severe psoriasis, and rheumatoid arthritis. It inhibits DNA synthesis and cell reproduction, primarily in actively proliferating cells such as malignant cells, trophoblasts, and fetal cells.",
"   </p>",
"   <p>",
"    MTX is rapidly cleared from the body by the kidneys, with 90 percent of an intravenous (IV) dose excreted unchanged within 24 hours of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of MTX used to treat ectopic pregnancy (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or 1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is relatively low. High dose MTX (&ge;500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    is used to treat some malignancies.",
"   </p>",
"   <p>",
"    In some protocols, reduced folates (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    , also called folinic acid, N5-formyl-tetrahydrofolate, citrovorum factor) are given to bypass the metabolic block induced by MTX, and thus rescue normal cells from toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=see_link&amp;anchor=H3#H3\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Clinical pharmacology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR MEDICAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Optimal candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal candidates for MTX treatment of ectopic pregnancy are hemodynamically stable, willing and able to comply with posttreatment follow-up, have a human chorionic gonadotropin beta-subunit (hCG) concentration &le;5000",
"    <span class=\"nowrap\">",
"     mIU/mL,",
"    </span>",
"    and no fetal cardiac activity. Ectopic mass size less than 3 to 4 cm is also commonly used as a patient selection criterion; however, this has not been confirmed as a predictor of successful treatment (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Relative contraindications'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women are not appropriate candidates for medical therapy and should be managed surgically, including women with the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamically unstable",
"     </li>",
"     <li>",
"      Signs of impending or ongoing ectopic mass rupture (ie, severe or persistent abdominal pain or &gt;300 mL of free peritoneal fluid outside the pelvic cavity)",
"     </li>",
"     <li>",
"      Clinically important abnormalities in baseline hematologic, renal or hepatic laboratory values",
"     </li>",
"     <li>",
"      Immunodeficiency, active pulmonary disease, peptic ulcer disease",
"     </li>",
"     <li>",
"      Hypersensitivity to MTX",
"     </li>",
"     <li>",
"      Coexistent viable intrauterine pregnancy",
"     </li>",
"     <li>",
"      Breastfeeding",
"     </li>",
"     <li>",
"      Unwilling or unable to be compliant with post-therapeutic monitoring",
"     </li>",
"     <li>",
"      Do not have timely access to a medical institution",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MTX is renally cleared, and in women with renal insufficiency, a single dose of MTX can lead to death or severe complications, including bone marrow suppression, acute respiratory distress syndrome and bowel ischemia. Dialysis does not provide normal renal clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Relative contraindications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High hCG concentration &mdash; A high serum hCG concentration is the most important factor associated with treatment failure (",
"      <a class=\"graphic graphic_table graphicRef74836 \" href=\"UTD.htm?14/35/14907\">",
"       table 1",
"      </a>",
"      ). Women with a high baseline hCG concentration (greater than 5000",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      are more likely to require multiple courses of medical therapy or experience treatment failure [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A systematic review of observational studies involved 503 women in which the outcome of single dose MTX therapy was stratified according to initial hCG concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/11\">",
"       11",
"      </a>",
"      ]. There was a statistically significant increase in failure rates in patients with initial hCG levels of greater than 5000",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      compared with those who had initial levels of less than 5000",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      (OR 5.5, 95% CI 3.0-9.8). The failure rate for women who had an initial concentration between 5000 and 9999",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      was significantly higher than for those who had initial levels between 2000 and 4999",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      (OR 3.8, 95% CI 1.2-12.3). Multiple dose regimens were not evaluated.",
"      <br/>",
"      <br/>",
"      The authors calculated that for every 10 treatments, there would be one more failure if the hCG level is 5000 to 9999",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      than there would be if it is 2000 to 4999",
"      <span class=\"nowrap\">",
"       mIU/mL.",
"      </span>",
"     </li>",
"     <li>",
"      Fetal cardiac activity &mdash; The presence of fetal cardiac activity is another relative contraindication to medical treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3,12\">",
"       3,12",
"      </a>",
"      ]. In a metaanalysis, sonographic evidence of cardiac activity was significantly associated with treatment failure (OR 9.1, 95% CI 3.8-22.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large ectopic size &mdash; Although large size of the ectopic pregnancy (&ge;3.5 cm) is often used as criterion for exclusion in medical treatment regimens, this restriction is based on small studies with inconsistent protocols and results [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/12-15\">",
"       12-15",
"      </a>",
"      ]. Studies have generally restricted use of MTX to women with an ectopic mass less than 3 to 4 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/12,13\">",
"       12,13",
"      </a>",
"      ], thus there are few studies of larger masses [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/16\">",
"       16",
"      </a>",
"      ]. As an example, one observational study found that the success rate for systematic MTX treatment was higher for women with ectopic masses smaller than 3.5 cm compared to masses between 3.5 and 4 cm (93 versus 90 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In addition, there are variations within and among studies regarding whether the size used is the actual gestational mass or the mass and surrounding hematoma [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. Further, ectopic mass size does not appear to correlate with hCG level [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peritoneal fluid &mdash; The sonographic finding of free peritoneal fluid is another commonly used exclusion criterion for MTX treatment of ectopic pregnancy. Peritoneal fluid may be blood, however, this is not diagnostic of tubal rupture; peritoneal blood may also be the result of tubal abortion. Historically, culdocenteses detected blood in the peritoneal cavity of 70 to 83 percent of women with ectopic pregnancies, but only 50 to 62 percent of them had a ruptured fallopian tube [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/18-20\">",
"       18-20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a large case series, free fluid confined to the pelvic cavity was not associated with medical treatment failure [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/12\">",
"       12",
"      </a>",
"      ]. While surgical treatment of patients with free fluid in the paracolic gutters or upper abdomen may be prudent, the amount of allowable free fluid confined to the posterior cul-de-sac (pouch of Douglas) is controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/7,21\">",
"       7,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other &mdash; Preliminary reports have cited a variety of other factors which may be associated with treatment failure. These include: sonographic evidence of a yolk sac [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/12,22,23\">",
"       12,22,23",
"      </a>",
"      ], isthmic location of ectopic mass (rather than ampullary) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/12,24\">",
"       12,24",
"      </a>",
"      ], high pretreatment",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      level [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/25\">",
"       25",
"      </a>",
"      ], and rate of hCG rise or fall prior to and within several days following treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/24,26\">",
"       24,26",
"      </a>",
"      ]. Further study is needed to validate these findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, women who are planning sterilization may desire concomitant surgical treatment for ectopic pregnancy and tubal ligation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DRUG ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX can be given systemically (intravenously, intramuscularly, or orally) or by direct local injection into the ectopic pregnancy sac transvaginally or laparoscopically. Intramuscular (IM) administration is most common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intramuscular therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramuscular MTX administration is the predominant route for treatment of tubal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local injection &mdash; Local injection of MTX for ectopic pregnancy is rarely used. Local treatment is highly operator dependent and not practical when performed laparoscopically. Women bearing the costs and risks of laparoscopic surgery should have definitive treatment (ie, removal of the ectopic gestation) at the time of the procedure.",
"      <br/>",
"      <br/>",
"      A systematic review found that treatment success with local injection of MTX may be higher than with systemic treatment; however, the difference did not reach statistical significance [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/27\">",
"       27",
"      </a>",
"      ]. In addition, local and systemic MTX administration had similar rates of subsequent intrauterine pregnancies or repeat ectopic pregnancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Efficacy of single versus multidose therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most commonly used protocols for MTX administration are single dose and multiple dose (four MTX doses which alternate with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ). Fourteen percent of patients on single dose regimens ultimately receive two or more doses and 10 percent of patients on multi-dose regimens receive a single dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3\">",
"     3",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H13\">",
"     'Single dose protocol'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Multiple dose protocol'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    We prefer an initial approach with single dose therapy for tubal ectopic pregnancy for the following reasons. The overall rate of resolution of ectopic pregnancy reported in the literature is about 90 percent for both single and multiple dose protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3,27,28\">",
"     3,27,28",
"    </a>",
"    ]. Multiple dose protocols appear to cause more adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3\">",
"     3",
"    </a>",
"    ]. The single dose approach is less expensive, requires less intensive monitoring, and does not require folinic acid rescue. The following are systematic reviews of the two regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of two randomized trials compared single dose with fixed multiple dose regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/27\">",
"       27",
"      </a>",
"      ]. There was no significant difference between treatment success rates, which ranged from 89 to 91 percent for single dose and 86 to 93 percent for multidose therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. There were no consistent findings regarding rates of complications between the two dose regimens.",
"     </li>",
"     <li>",
"      Another systematic review included 26 observational studies of 1300 women with ectopic pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3\">",
"       3",
"      </a>",
"      ]. Overall success rates for single versus multiple dose regimens were 88 and 93 percent, a significant difference. This difference was even larger after adjustment for factors such as hCG concentration and presence of embryonic cardiac activity (OR 4.74, 95 percent CI 1.77-12.62). However, significantly fewer side effects were noted after single dose versus multidose treatment (31 versus 41 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A hybrid of the two protocols, a two-dose MTX regimen (50",
"    <span class=\"nowrap\">",
"     mg/m",
"    </span>",
"    2 IM on days 0 and 4) has been proposed. A single report on this regimen found an 87 percent treatment success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/31\">",
"     31",
"    </a>",
"    ], infrequent complications and adverse effects, and high patient satisfaction. Further study to evaluate this protocol is needed before it can be recommended.",
"   </p>",
"   <p>",
"    On the other hand, we use multidose MTX therapy for interstitial pregnancies (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Interstitial pregnancy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Combination therapy with mifepristone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of ectopic pregnancy using a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and MTX has also been investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/27\">",
"     27",
"    </a>",
"    ]. A systematic review of randomized trials of single dose intramuscular MTX (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    in combination with oral mifepristone (600 mg) versus MTX alone found that combination therapy may increase treatment efficacy. Success rates for MTX or",
"    <span class=\"nowrap\">",
"     MTX/mifepristone",
"    </span>",
"    therapy were 81 and 74 percent; the difference approached statistical significance. No differences were found in tubal preservation or tubal patency. No data are available on future fertility. More studies are needed to fully evaluate whether the addition of mifepristone to MTX regimens is beneficial.",
"   </p>",
"   <p>",
"    We do not recommend the use of this regimen. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    is not approved for treatment of ectopic pregnancy in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pretreatment testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCG, blood type, complete blood count, renal and liver function tests are drawn prior to starting therapy. A transvaginal ultrasound is performed. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Contraindications'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rh(D) immune globulin should be administered if the woman is Rh(D)-negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not perform endometrial sampling in the management of ectopic pregnancy. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is a less invasive option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Precautions during therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and clinicians should adhere to the following precautions during MTX treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoid vaginal intercourse and new conception until hCG is undetectable",
"     </li>",
"     <li>",
"      Avoid pelvic exams during surveillance of MTX therapy due to theoretical risk of tubal rupture",
"     </li>",
"     <li>",
"      Avoid sun exposure to limit risk of MTX dermatitis",
"     </li>",
"     <li>",
"      Avoid foods and vitamins containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"     </li>",
"     <li>",
"      Avoid nonsteroidal antiinflammatory drugs, as the interaction with MTX may cause bone marrow suppression, aplastic anemia, or gastrointestinal toxicity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Single dose protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most efficient approach to medical therapy is administration of a single IM dose of MTX. Approximately 15 to 20 percent of women will require a second dose of MTX and patients should be made aware of this before starting the protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. Fewer than 1 percent of patients need more than two doses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3\">",
"     3",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H17\">",
"     'Side effects and complications'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In the single dose protocol (",
"    <a class=\"graphic graphic_table graphicRef56738 \" href=\"UTD.htm?21/33/22045\">",
"     table 2",
"    </a>",
"    ), Day 1 is the day that MTX is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. The dose used is 50 mg per square meter of body surface area (BSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/33\">",
"     33",
"    </a>",
"    ]. BSA may be calculated based upon height and weight on the day of treatment using the formula BSA = square root ((cm X",
"    <span class=\"nowrap\">",
"     kg)/3600)",
"    </span>",
"    or a BSA calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/27/4529?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). Protocols vary slightly; choice of protocol depends on provider preference.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a commonly used protocol, on Days 4 and 7, a serum hCG concentration is drawn [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/7,8,34\">",
"       7,8,34",
"      </a>",
"      ]. If the decrease in hCG between Days 4 and 7 is less than 15 percent, a",
"      <strong>",
"       second",
"      </strong>",
"      dose of MTX 50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IM is administered. It is common to observe an increase in hCG levels in the first several days following therapy (ie, until Day 4) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/35\">",
"       35",
"      </a>",
"      ]. This is due to continued hCG production by syncytiotrophoblast despite cessation of production by cytotrophoblast.",
"     </li>",
"     <li>",
"      In our practice, we prefer to draw the second hCG level on Day 7, thereby saving the patient a visit on Day 4 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/36\">",
"       36",
"      </a>",
"      ]. Data from a study of hCG values on Days 1, 4, and 7 suggest that Day 4 serum hCG levels is not an accurate test to predict treatment success [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/37\">",
"       37",
"      </a>",
"      ]. We administer a",
"      <strong>",
"       second",
"      </strong>",
"      dose of MTX if the serum hCG concentration on Day 7 has not declined by at least 25 percent from the Day 1 level, and the protocol is repeated.",
"     </li>",
"     <li>",
"      If an additional dose of MTX is indicated, we do not repeat pretreatment laboratory testing (complete blood count, renal and liver function tests); there are no data suggesting that one dose of MTX changes the results of these tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After Day 7, hCG testing is repeated weekly. On Day 14, if there is a &lt;15 percent hCG decline from Days 7 to 14, a",
"    <strong>",
"     third",
"    </strong>",
"    dose of MTX 50",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    IM is given. If there is a &ge;15 percent hCG decline from Days 7 to 14, check hCG weekly until the level is undetectable (this level varies by laboratory). The hCG concentration usually declines to less than 15",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    by 35 days post-injection, but may take as long as 109 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/13,38\">",
"     13,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We give a maximum of three doses of MTX. If the hCG falls &lt;15 percent between weekly measurements after a third dose, we perform a laparoscopic salpingostomy or salpingectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=see_link\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Folinic acid rescue is not required for women treated with the single dose protocol, even if multiple doses are ultimately given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Multiple dose protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common multiple dose regimen administers MTX (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IM or IV) on Days 1, 3, 5, and 7, and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    on Days 2, 4, 6, and 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/39\">",
"     39",
"    </a>",
"    ]. HCG levels are drawn on Days 1, 3, 5, and 7. If the serum hCG declines MORE than 15 percent from the previous measurement, treatment is stopped and a surveillance phase begins.",
"   </p>",
"   <p>",
"    The surveillance phase consists of weekly hCG measurements. If the hCG declines LESS than 15 percent from the previous level, the patient is given an additional dose of MTX 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IM followed the next day with a dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    The hCG is followed until the level is undetectable.",
"   </p>",
"   <p>",
"    A systematic review of patients treated with multiple dose regimens found a 93 percent success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3\">",
"     3",
"    </a>",
"    ]. Forty percent of women reported side effects, but these effects were relatively minor and transient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Posttreatment management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ultrasound follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be no clinical benefit from routine serial ultrasound examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/17\">",
"     17",
"    </a>",
"    ]. After treatment, the ectopic pregnancy is often noted to increase in size and may persist for weeks on serial ultrasound examinations. This probably represents hematoma, rather than persistent trophoblastic tissue, and is not predictive of treatment failure. However, ultrasound evaluation for peritoneal fluid is indicated for women with severe abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Side effects and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions to MTX are usually mild and self-limited. The most common are stomatitis and conjunctivitis. Rare side effects include gastritis, enteritis, dermatitis, pneumonitis, alopecia, elevated liver enzymes, and bone marrow suppression. Approximately 30 percent of patients in the single dose protocol will have side effects; this rate is lower than with multidose regimens (40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pain after treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild abdominal pain of short duration (one to two days) six to seven days after receiving the medication is also common. The pain may be due to tubal abortion or tubal distention from hematoma formation and can usually be controlled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . Nonsteroidal antiinflammatory drugs should be avoided because a clinically significant drug interaction with MTX occurs in some patients taking both drugs.",
"   </p>",
"   <p>",
"    Occasionally pain may be severe, but women with severe pain who are hemodynamically stable often do not need surgical intervention. As an example, a review of 56 women with abdominal pain severe enough to be evaluated in the clinic or emergency department, or requiring hospitalization, found that only eight patients subsequently required surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A patient with severe pain may be further evaluated with transvaginal ultrasonography. Findings suggestive of hemoperitoneum raise clinical suspicion of tubal rupture. In one study, three parameters predicted hemoperitoneum &ge;300 mL in women with ectopic pregnancy: moderate to severe pelvic pain, fluid above the uterine fundus or around the ovary, and serum hemoglobin concentration &lt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/40\">",
"     40",
"    </a>",
"    ]. A woman with none of these three criteria had a probability of 5.3 percent of hemoperitoneum &ge;300 ml. When two or more criteria were present, the probability for hemoperitoneum &ge;300 ml reached 92.6 percent.",
"   </p>",
"   <p>",
"    Women with severe pain should be closely observed for hemodynamic changes which may accompany a tubal rupture. Falling hCG levels do not preclude the possibility of tubal rupture. If tubal rupture is suspected, immediate surgery is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUBSEQUENT REPRODUCTIVE PERFORMANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26079278\">",
"    <span class=\"h2\">",
"     Interval to conception",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been no study addressing when is the earliest and best time to conceive after MTX treatment of ectopic pregnancy. One study reported that patients with ectopic pregnancies treated with MTX had a timely return of menses and superior rates of conception compared with those treated with conservative surgical management [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/41\">",
"     41",
"    </a>",
"    ]. However, a retrospective study of controlled ovarian hyperstimulation after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    treatment of ectopic pregnancy reported decreased number of oocytes in the cycle within 180 days after methotrexate compared to that in later days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxicology literature recommends a four to six month washout period [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A retrospective study of women who conceive after MTX treatment for ectopic pregnancy found no difference in fetal malformation and adverse outcome rates in those who conceived within less than six months (mean 3.6&plusmn;1.7 months) compared with six or more months (mean 23.6&plusmn;14.7 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, since, there is no apparent deleterious effect of previous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    treatment on the offspring, it is reasonable to allow the patients to conceive. Women in this population should take the folate daily, according to routine preconceptual recommendations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link&amp;anchor=H7#H7\">",
"     \"Folic acid for prevention of neural tube defects\", section on 'Folic acid supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26079286\">",
"    <span class=\"h2\">",
"     Effect on fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of adverse effects of MTX treatment of ectopic pregnancy on future pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. In addition, treatment with MTX does not appear to compromise ovarian reserve [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/50\">",
"     50",
"    </a>",
"    ]. Attempts to conceive may be resumed after the hCG level is undetectable.",
"   </p>",
"   <p>",
"    Extrauterine pregnancy is usually due to altered tubal function secondary to clinical or subclinical salpingitis; the functional disorder is bilateral and irreversible. Therefore, it is not surprising that ectopic pregnancy can be followed by infertility and recurrent ectopic pregnancy.",
"   </p>",
"   <p>",
"    The incidence of recurrent ectopic pregnancy is approximately 15 percent and rises to 30 percent following two ectopic pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/51\">",
"     51",
"    </a>",
"    ]. The risk of recurrence appears to be the same for both medical and surgical therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Medical versus surgical treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The initial level of hCG &gt;5000",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    may be associated with increased risk of subsequent tubal obstruction, regardless of treatment approach [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MEDICAL VERSUS SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 35 percent of women with ectopic pregnancy are eligible for medical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/2\">",
"     2",
"    </a>",
"    ]. In these women, systemic treatment with MTX is as effective as laparoscopic salpingostomy, and results in similar success rates for tubal patency and future intrauterine pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/54\">",
"     54",
"    </a>",
"    ]. Although adverse effects are increased with MTX over surgery, depending on the MTX regimen (fixed multiple dose versus",
"    <span class=\"nowrap\">",
"     single/variable",
"    </span>",
"    dose), patient recovery may be improved with medical treatment. Medical treatment costs approximately $3000 less than surgery per resolved ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who are eligible for either medical or surgical treatment, the choice of therapy should be guided by the patient's preference after a detailed discussion of risks, benefits, outcome, and monitoring requirements of both medical and surgical approaches. Informed consent is obtained before administration of MTX, as well as before surgery.",
"   </p>",
"   <p>",
"    A systemic review of randomized trials compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy with laparoscopic salpingostomy; major findings are listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intramuscular MTX therapy (single or multiple dose) and salpingostomy yielded similar treatment success rates, ranging from 82 to 95 percent for MTX therapy versus 80 to 92 percent for salpingostomy. Transvaginal injection of MTX was significantly less effective than salpingostomy.",
"     </li>",
"     <li>",
"      Adverse effects and complications were more common in women treated with systemic MTX than with surgery (60 versus 12 percent in one study). However, the studies were likely underpowered to detect a difference in rare perioperative complications.",
"     </li>",
"     <li>",
"      Physical and psychological functioning after treatment was improved for patients treated with single dose MTX compared to laparoscopic salpingostomy; however, women treated with multidose regimens showed greater functional impairment than their surgical counterparts.",
"     </li>",
"     <li>",
"      The time required for hCG concentrations to reach undetectable levels is faster after laparoscopic surgery, thus reducing the period of posttreatment monitoring, based on the only randomized trial to report this outcome.",
"     </li>",
"     <li>",
"      Posttreatment tubal patency and intrauterine pregnancy rates were similar.",
"     </li>",
"     <li>",
"      Risk of recurrent ectopic pregnancy did not differ by treatment approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MEDICAL TREATMENT VERSUS EXPECTANT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectant management should only be considered by women with unknown location of their pregnancy or suspected ectopic pregnancy, and low and declining serum hCG levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21444?source=see_link\">",
"     \"Expectant management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INTERSTITIAL PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We initially treat interstitial pregnancy (located at the junction of the fallopian tube and uterine cavity) with multidose medical therapy (",
"    <a class=\"graphic graphic_figure graphicRef55921 \" href=\"UTD.htm?10/35/10804\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/39,55-58\">",
"     39,55-58",
"    </a>",
"    ], resorting to surgical therapy if there is any deterioration in clinical status. There are no high quality data comparing single versus multidose MTX therapy for interstitial pregnancy.",
"   </p>",
"   <p>",
"    The most common multiple dose regimen administers MTX (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IM or IV) on Days 1, 3, 5, and 7 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally) on Days 2, 4, 6, and 8; a second course of",
"    <span class=\"nowrap\">",
"     MTX/leucovorin",
"    </span>",
"    may be given seven days after the last dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/39\">",
"     39",
"    </a>",
"    ]. Success rates of 66 to 100 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/57\">",
"     57",
"    </a>",
"    ]. In one study, the mean duration to achieve an undetectable serum hCG concentration was 43 &plusmn; 64 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A residual interstitial mass or heterogeneous area with persistent vascularity on ultrasound has been reported despite complete hCG resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Close follow-up in patients treated medically is advised. In those with increasing abdominal pain, early surgical intervention should be considered. After medical treatment of an interstitial pregnancy, there is an unknown risk of uterine rupture in a future pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also case reports of management of interstitial pregnancy using selective arterial embolization alone or with MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27417/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical treatment of interstitial pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=see_link&amp;anchor=H10#H10\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\", section on 'Cornuostomy or cornual resection of interstitial pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NONTUBAL ECTOPIC PREGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical and surgical management of heterotopic, cervical, cesarean scar, or abdominal pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=see_link\">",
"     \"Cervical pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=see_link\">",
"       \"Patient information: Ectopic pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=see_link\">",
"       \"Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ideal candidates for MTX treatment are women with ectopic pregnancy who meet the following criteria (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Candidates for medical treatment'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemodynamically stable",
"     </li>",
"     <li>",
"      Able and willing to comply with posttreatment monitoring",
"     </li>",
"     <li>",
"      Pretreatment serum hCG concentration less than 5000",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"     </li>",
"     <li>",
"      Tubal size of less than 3 to 4 cm and no fetal cardiac activity (these are not independent predictors of MTX treatment success)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal, hepatic, or hematologic disorders are contraindications to treatment with MTX. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pretreatment testing includes: hCG, blood type, complete blood count, renal and liver function tests, and transvaginal ultrasound. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pretreatment testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In single dose protocols, intramuscular MTX is given followed by a hCG level on treatment Day 7 (or Days 4 and 7) and then weekly. Additional doses of MTX are given if the hCG does not decline sufficiently. The hCG is followed until the level is undetectable. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Single dose protocol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In multiple dose protocols, MTX is given on Days 1, 3, 5, and 7 and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      on Days 2, 4, 6, and 8. If the serum hCG concentration plateaus or increases in two consecutive measurements, a second course may be given seven days after the previous dose. HCG is followed weekly until undetectable. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Multiple dose protocol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine ultrasound follow-up is not necessary during treatment. After treatment, the ectopic pregnancy often increases in size and may persist for weeks. However, ultrasound evaluation for peritoneal fluid is indicated for women who develop severe abdominal pain. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Ultrasound follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild abdominal pain of short duration (one to two days) that occurs six to seven days after receiving the medication is common. Women with severe pain should be observed closely for hemodynamic changes which may accompany a tubal rupture. Clinical suspicion of a tubal rupture is an indication for immediate surgery. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Pain after treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with MTX does not appear to compromise future fertility or pregnancy outcome, or increase the risk of recurrent ectopic pregnancy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Subsequent reproductive performance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with a pregnancy of unknown location or suspected ectopic pregnancy, and low and declining serum hCG levels may be candidates for expectant management. There are no high quality studies which compare expectant and medical treatment. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Medical treatment versus expectant management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with ectopic pregnancy who are hemodynamically unstable require surgery. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Candidates for medical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with tubal ectopic pregnancy, who are good candidates for MTX therapy (hemodynamically stable, able to comply with follow-up, hCG &lt;5000",
"      <span class=\"nowrap\">",
"       mIU/mL,",
"      </span>",
"      no fetal cardiac activity), we suggest MTX therapy rather than laparoscopic surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In stable women who do not meet these criteria, we suggest laparoscopic surgery rather than MTX (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Medical versus surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend use of systemic over local injection of MTX (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intramuscular therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a single dose over multiple dose regimen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, we use a multidose regimen for interstitial pregnancy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Efficacy of single versus multidose therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      with MTX rather than MTX alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Combination therapy with mifepristone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women who have been treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      for tubal or interstitial pregnancy, we suggest that attempts to conceive may be resumed after the hCG level is undetectable rather than waiting for one or more ovulatory cycles (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Subsequent reproductive performance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/1\">",
"      Lipscomb GH. Medical therapy for ectopic pregnancy. Semin Reprod Med 2007; 25:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/2\">",
"      Van Den Eeden SK, Shan J, Bruce C, Glasser M. Ectopic pregnancy rate and treatment utilization in a large managed care organization. Obstet Gynecol 2005; 105:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/3\">",
"      Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing \"single dose\" and \"multidose\" regimens. Obstet Gynecol 2003; 101:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/4\">",
"      Farquhar CM. Ectopic pregnancy. Lancet 2005; 366:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/5\">",
"      Morlock RJ, Lafata JE, Eisenstein D. Cost-effectiveness of single-dose methotrexate compared with laparoscopic treatment of ectopic pregnancy. Obstet Gynecol 2000; 95:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/6\">",
"      Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/7\">",
"      Practice Committee of the American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy. Fertil Steril 2006; 86:S96.",
"     </a>",
"    </li>",
"    <li>",
"     Medical management of ectopic pregnancy. ACOG Practice Bulletin #94. American College of Obstetricians and Gynecologists, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/9\">",
"      Kelly H, Harvey D, Moll S. A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy. Obstet Gynecol 2006; 107:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/10\">",
"      Teal SB. A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy. Obstet Gynecol 2006; 107:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/11\">",
"      Menon S, Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007; 87:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/12\">",
"      Lipscomb GH, McCord ML, Stovall TG, et al. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med 1999; 341:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/13\">",
"      Lipscomb GH, Bran D, McCord ML, et al. Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstet Gynecol 1998; 178:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/14\">",
"      Shalev E, Peleg D, Bustan M, et al. Limited role for intratubal methotrexate treatment of ectopic pregnancy. Fertil Steril 1995; 63:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/15\">",
"      Nazac A, Gervaise A, Bouyer J, et al. Predictors of success in methotrexate treatment of women with unruptured tubal pregnancies. Ultrasound Obstet Gynecol 2003; 21:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/16\">",
"      Tzafettas JM, Stephanatos A, Loufopoulos A, et al. Single high dose of local methotrexate for the management of relatively advanced ectopic pregnancies. Fertil Steril 1999; 71:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/17\">",
"      Gamzu R, Almog B, Levin Y, et al. The ultrasonographic appearance of tubal pregnancy in patients treated with methotrexate. Hum Reprod 2002; 17:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/18\">",
"      Romero R, Copel JA, Kadar N, et al. Value of culdocentesis in the diagnosis of ectopic pregnancy. Obstet Gynecol 1985; 65:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/19\">",
"      Vermesh M, Graczykowski JW, Sauer MV. Reevaluation of the role of culdocentesis in the management of ectopic pregnancy. Am J Obstet Gynecol 1990; 162:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/20\">",
"      Cartwright PS, Vaughn B, Tuttle D. Culdocentesis and ectopic pregnancy. J Reprod Med 1984; 29:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/21\">",
"      Lipscomb GH, Puckett KJ, Bran D, Ling FW. Management of separation pain after single-dose methotrexate therapy for ectopic pregnancy. Obstet Gynecol 1999; 93:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/22\">",
"      Bixby S, Tello R, Kuligowska E. Presence of a yolk sac on transvaginal sonography is the most reliable predictor of single-dose methotrexate treatment failure in ectopic pregnancy. J Ultrasound Med 2005; 24:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/23\">",
"      Potter MB, Lepine LA, Jamieson DJ. Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital. Am J Obstet Gynecol 2003; 188:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/24\">",
"      Dudley PS, Heard MJ, Sangi-Haghpeykar H, et al. Characterizing ectopic pregnancies that rupture despite treatment with methotrexate. Fertil Steril 2004; 82:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/25\">",
"      Takacs P, Rodriguez L. High folic acid levels and failure of single-dose methotrexate treatment in ectopic pregnancy. Int J Gynaecol Obstet 2005; 89:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/26\">",
"      da Costa Soares R, Elito J Jr, Camano L. Increment in beta-hCG in the 48-h period prior to treatment: a new variable predictive of therapeutic success in the treatment of ectopic pregnancy with methotrexate. Arch Gynecol Obstet 2008; 278:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/27\">",
"      Hajenius PJ, Mol BW, Bossuyt PM, et al. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev 2000; :CD000324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/28\">",
"      Lipscomb GH, Givens VM, Meyer NL, Bran D. Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy. Am J Obstet Gynecol 2005; 192:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/29\">",
"      Alleyassin A, Khademi A, Aghahosseini M, et al. Comparison of success rates in the medical management of ectopic pregnancy with single-dose and multiple-dose administration of methotrexate: a prospective, randomized clinical trial. Fertil Steril 2006; 85:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/30\">",
"      Klauser, CK, May, WL, Johnson, VK, et al. Methotrexate for ectopic pregnancy: a randomized single dose compared with multiple dose. Obstetrics and Gynaecology 2005; 105:64S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/31\">",
"      Barnhart K, Hummel AC, Sammel MD, et al. Use of \"2-dose\" regimen of methotrexate to treat ectopic pregnancy. Fertil Steril 2007; 87:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/32\">",
"      Stovall TG, Ling FW, Gray LA, et al. Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases. Obstet Gynecol 1991; 77:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/33\">",
"      Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol 1993; 168:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/34\">",
"      Kirk E, Condous G, Van Calster B, et al. A validation of the most commonly used protocol to predict the success of single-dose methotrexate in the treatment of ectopic pregnancy. Hum Reprod 2007; 22:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/35\">",
"      Natale A, Candiani M, Barbieri M, et al. Pre- and post-treatment patterns of human chorionic gonadotropin for early detection of persistence after a single dose of methotrexate for ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 117:87.",
"     </a>",
"    </li>",
"    <li>",
"     Bisharah, M, Tulandi, T. Practical management of ectopic pregnancy. In: Reproductive Endocrinology and Infertility. Current trends and developments. Tan, SL and Tulandi, T (eds), Marcel Dekker, New York 2003. p. 225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/37\">",
"      Gabbur N, Sherer DM, Hellmann M, et al. Do serum beta-human chorionic gonadotropin levels on day 4 following methotrexate treatment of patients with ectopic pregnancy predict successful single-dose therapy? Am J Perinatol 2006; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/38\">",
"      Saraj AJ, Wilcox JG, Najmabadi S, et al. Resolution of hormonal markers of ectopic gestation: a randomized trial comparing single-dose intramuscular methotrexate with salpingostomy. Obstet Gynecol 1998; 92:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/39\">",
"      Stovall TG, Ling FW, Buster JE. Outpatient chemotherapy of unruptured ectopic pregnancy. Fertil Steril 1989; 51:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/40\">",
"      Fauconnier A, Mabrouk A, Salomon LJ, et al. Ultrasound assessment of haemoperitoneum in ectopic pregnancy: derivation of a prediction model. World J Emerg Surg 2007; 2:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/41\">",
"      Stovall TG, Ling FW, Buster JE. Reproductive performance after methotrexate treatment of ectopic pregnancy. Am J Obstet Gynecol 1990; 162:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/42\">",
"      McLaren JF, Burney RO, Milki AA, et al. Effect of methotrexate exposure on subsequent fertility in women undergoing controlled ovarian stimulation. Fertil Steril 2009; 92:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/43\">",
"      Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1986; 1:81.",
"     </a>",
"    </li>",
"    <li>",
"     Strauss, JF, Williams, CJ. The ovarian life cycle. In: Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 5th ed, Strauss, JF, Barbieri, RL (Eds), Elsevier Saunders, Philadelphia 2004. p.213.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/45\">",
"      Svirsky R, Rozovski U, Vaknin Z, et al. The safety of conception occurring shortly after methotrexate treatment of an ectopic pregnancy. Reprod Toxicol 2009; 27:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/46\">",
"      Pektasides D, Rustin GJ, Newlands ES, et al. Fertility after chemotherapy for ovarian germ cell tumours. Br J Obstet Gynaecol 1987; 94:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/47\">",
"      Ayhan A, Ergeneli MH, Y&uuml;ce K, et al. Pregnancy after chemotherapy for gestational trophoblastic disease. J Reprod Med 1990; 35:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/48\">",
"      Keefe KA, Wald JS, Goldstein DP, et al. Reproductive outcome after methotrexate treatment of tubal pregnancies. J Reprod Med 1998; 43:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/49\">",
"      Kung FT, Chang SY, Tsai YC, et al. Subsequent reproduction and obstetric outcome after methotrexate treatment of cervical pregnancy: a review of original literature and international collaborative follow-up. Hum Reprod 1997; 12:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/50\">",
"      Oriol B, Barrio A, Pacheco A, et al. Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve. Fertil Steril 2008; 90:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/51\">",
"      Tulandi T. Reproductive performance of women after two tubal ectopic pregnancies. Fertil Steril 1988; 50:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/52\">",
"      Gervaise A, Masson L, de Tayrac R, et al. Reproductive outcome after methotrexate treatment of tubal pregnancies. Fertil Steril 2004; 82:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/53\">",
"      Elito J Jr, Han KK, Camano L. Values of beta-human chorionic gonadotropin as a risk factor for tubal obstruction after tubal pregnancy. Acta Obstet Gynecol Scand 2005; 84:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/54\">",
"      Hajenius PJ, Mol F, Mol BW, et al. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev 2007; :CD000324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/55\">",
"      Tulandi T, Al-Jaroudi D. Interstitial pregnancy: results generated from the Society of Reproductive Surgeons Registry. Obstet Gynecol 2004; 103:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/56\">",
"      Lau S, Tulandi T. Conservative medical and surgical management of interstitial ectopic pregnancy. Fertil Steril 1999; 72:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/57\">",
"      Jermy K, Thomas J, Doo A, Bourne T. The conservative management of interstitial pregnancy. BJOG 2004; 111:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/58\">",
"      Moawad NS, Mahajan ST, Moniz MH, et al. Current diagnosis and treatment of interstitial pregnancy. Am J Obstet Gynecol 2010; 202:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/59\">",
"      Verity L, Ludlow J, Dickinson JE. Interstitial ectopic pregnancy: a contemporary case series. Aust N Z J Obstet Gynaecol 2003; 43:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/60\">",
"      Tang A, Baartz D, Khoo SK. A medical management of interstitial ectopic pregnancy: a 5-year clinical study. Aust N Z J Obstet Gynaecol 2006; 46:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/61\">",
"      Downey GP, Tuck SM. Spontaneous uterine rupture during subsequent pregnancy following non-excision of an interstitial ectopic gestation. Br J Obstet Gynaecol 1994; 101:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/62\">",
"      Deruelle P, Lucot JP, Lions C, Robert Y. Management of interstitial pregnancy using selective uterine artery embolization. Obstet Gynecol 2005; 106:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27417/abstract/63\">",
"      Ophir E, Singer-Jordan J, Oettinger M, et al. Uterine artery embolization for management of interstitial twin ectopic pregnancy: case report. Hum Reprod 2004; 19:1774.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5407 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27417=[""].join("\n");
var outline_f26_49_27417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CANDIDATES FOR MEDICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Optimal candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DRUG ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intramuscular therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Efficacy of single versus multidose therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Combination therapy with mifepristone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pretreatment testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Precautions during therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Single dose protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Multiple dose protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Posttreatment management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ultrasound follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Side effects and complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pain after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUBSEQUENT REPRODUCTIVE PERFORMANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26079278\">",
"      Interval to conception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26079286\">",
"      Effect on fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MEDICAL VERSUS SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MEDICAL TREATMENT VERSUS EXPECTANT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INTERSTITIAL PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NONTUBAL ECTOPIC PREGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5407\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5407|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/35/10804\" title=\"figure 1\">",
"      Normal female anat detail",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5407|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/35/14907\" title=\"table 1\">",
"      Success single dose MTX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/33/22045\" title=\"table 2\">",
"      MTX ectopic preg protocol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?4/27/4529?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Surface Area (Mosteller, square root method)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=related_link\">",
"      Cervical pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21444?source=related_link\">",
"      Expectant management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=related_link\">",
"      Mifepristone for the medical termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=related_link\">",
"      Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=related_link\">",
"      Patient information: Ectopic pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=related_link\">",
"      Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_49_27418="Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis";
var content_f26_49_27418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27418/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27418/contributors\">",
"     Arun J Sanyal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27418/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27418/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/49/27418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/49/27418/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/49/27418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately half of patients with cirrhosis have esophageal varices, and one-third of all patients with varices will develop variceal hemorrhage, a major cause of morbidity and mortality in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The risk of hemorrhage has been related to the size and appearance of the varices, as well as the degree of hepatic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary prophylaxis aims to prevent variceal hemorrhage in patients with esophageal varices who do not have a history of hemorrhage. Pre-primary prophylaxis refers to measures aimed at preventing the development of varices. Measures aimed at preventing hemorrhage in patients with a history of variceal hemorrhage are referred to as secondary prophylaxis.",
"   </p>",
"   <p>",
"    An ideal treatment of portal hypertension would be one that is universally effective, safe, easy to administer, and cost-effective. While such a treatment does not currently exist, there are several medical and surgical modalities available for primary prophylaxis of variceal hemorrhage. These therapies are aimed at achieving one of the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreasing portal hypertension (eg, beta blockers, surgical portal decompression, or transjugular intrahepatic shunts)",
"     </li>",
"     <li>",
"      Treating the varices directly (eg, variceal ligation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the options available for primary and pre-primary prophylaxis of variceal hemorrhage in patients with cirrhosis. Issues related to predicting which patients are at increased risk for variceal hemorrhage and secondary prophylaxis in patients who have already had a variceal bleed are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H747040\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Association for the Study of Liver Diseases (AASLD) published",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     guidelines",
"    </a>",
"    in 2007 that address primary prophylaxis against variceal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/2\">",
"     2",
"    </a>",
"    ], and in 2010 the Baveno V consensus guidelines were published [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Baveno V consensus guidelines recommend primary prophylaxis with nonselective beta blockers for patients with small varices with red wale marks (",
"    <a class=\"graphic graphic_picture graphicRef50222 \" href=\"UTD.htm?7/25/7568\">",
"     picture 1",
"    </a>",
"    ) or Child C cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/3\">",
"     3",
"    </a>",
"    ]. They note that patients with small varices without signs of increased risk for hemorrhage (red wale marks) or Child C cirrhosis can be considered for treatment with nonselective beta blockers, but that further studies are needed to confirm a benefit to this approach. The guidelines also recommend that patients with medium or large varices be treated with beta blockers or EVL.",
"   </p>",
"   <p>",
"    The AASLD guidelines are similar to the Baveno guidelines and recommend prophylaxis with nonselective beta blockers for patients with compensated cirrhosis and small varices that have not bled but have criteria for increased risk of hemorrhage (Child B or C cirrhosis or presence of red wale marks). In addition, the guidelines state that nonselective beta blockers can be considered for patients with cirrhosis and small varices that have not bled and have no criteria for increased risk of hemorrhage. Finally, the guidelines recommend prophylaxis with nonselective beta blockers or EVL for patients with medium or large varices.",
"   </p>",
"   <p>",
"    Our approach to primary prophylaxis and the discussion that follows is largely consistent with these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PORTAL HEMODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the pathophysiology of portal hypertension is important in a discussion of therapies aimed at reducing portal pressure. Portal pressure is equal to the product of the portal venous inflow and the resistance to outflow from the portal venous system. Portal venous inflow is controlled by the tone of the mesenteric arterioles. Thus, a decrease in mesenteric arteriolar tone results in increases in portal venous inflow and consequently portal pressure. Normal portal pressure is between 5 and 10 mmHg.",
"   </p>",
"   <p>",
"    Outflow resistance from the portal system may be considered as two separate resistances in parallel. The first is due to resistance to flow through the portal vein, liver, and hepatic vein; the second is due to resistance to flow through collaterals from the portal system that independently drain into the systemic circulation. It is now recognized that the increase in resistance to flow within the liver is in part due to intrahepatic vasoconstriction secondary to impaired nitric oxide production within the liver. It is estimated that about 30 percent of the intrahepatic resistance may be reversible and is not due to fixed changes in the vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with cirrhosis, elevated portal pressure results from a combination of increased portal inflow due to splanchnic arteriolar vasodilation and elevated resistance to outflow through distorted hepatic sinusoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Varices decompress the portal vein and return blood to the systemic circulation in patients with portal hypertension. A normal pressure gradient between the portal and hepatic veins (the hepatic venous pressure gradient or HVPG) is 1 to 5 mmHG. Varices form when the pressure gradient between the portal and hepatic veins rises above 10 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, therapies aimed at decreasing portal venous pressure may decrease the formation of varices and the risk of variceal hemorrhage. (See",
"    <a class=\"local\" href=\"#H748332\">",
"     'Dose titration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SCREENING FOR VARICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with cirrhosis should undergo screening for esophageal varices so that prophylactic therapy can be given to those with varices that are at increased risk for bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H70835313\">",
"     'Primary prophylaxis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link&amp;anchor=H129709535#H129709535\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\", section on 'Predictive factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157005252\">",
"    <span class=\"h2\">",
"     Rationale behind screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying and treating patients with high-risk varices leads to improved clinical outcomes. Estimates are that 30 percent of patients with compensated cirrhosis and 60 percent of patients with decompensated cirrhosis have varices at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/7\">",
"     7",
"    </a>",
"    ]. The annual rate of a first hemorrhage episode among those with varices is 12 percent, and each episode of variceal hemorrhage is associated with up to a 15 to 20 percent risk of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/2,8-11\">",
"     2,8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have shown that primary prophylaxis with a nonselective beta blocker or endoscopic variceal ligation reduces the risk of first variceal hemorrhage and decreases the risk of bleeding-related mortality. In addition, overall mortality is lower in patients treated with endoscopic variceal ligation, and there is a trend toward decreased mortality in patients treated with nonselective beta blockers. (See",
"    <a class=\"local\" href=\"#H747559\">",
"     'Nadolol and propranolol'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H750670\">",
"     'Endoscopic variceal ligation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157005347\">",
"    <span class=\"h2\">",
"     Screening methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, screening is done with an upper endoscopy, though wireless video capsule endoscopy has also been used. In addition, the ratio of the platelet count to the spleen size (expressed as a standard deviation score) and clinical prediction rules that include platelet count, spleen size, and albumin have been shown to predict varices in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with compensated cirrhosis who do not have varices, screening is repeated every two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/2\">",
"     2",
"    </a>",
"    ]. In patients with decompensated cirrhosis (ie, patients who have developed complications from cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef65667 \" href=\"UTD.htm?0/56/907\">",
"     table 2",
"    </a>",
"    )), it is repeated every year or at the time of first decompensation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link&amp;anchor=H19#H19\">",
"     \"Wireless video capsule endoscopy\", section on 'Esophageal capsule endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If varices are present, they can be classified as (",
"    <a class=\"graphic graphic_picture graphicRef61770 \" href=\"UTD.htm?42/51/43838\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      F1: Small, straight varices",
"     </li>",
"     <li>",
"      F2: Enlarged, tortuous varices that occupy less than one-third of the lumen",
"     </li>",
"     <li>",
"      F3: Large, coil-shaped varices that occupy more than one-third of the lumen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, many hepatologists and endoscopists are now categorizing varices as either large or small, since medium-sized varices (F2) are managed in the same way large (F3) varices are.",
"   </p>",
"   <p>",
"    Patients at increased risk for variceal hemorrhage (those with Child B or C cirrhosis, larger varices,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    red signs on the varices (",
"    <a class=\"graphic graphic_picture graphicRef50222 \" href=\"UTD.htm?7/25/7568\">",
"     picture 1",
"    </a>",
"    )) should receive primary prophylaxis (",
"    <a class=\"graphic graphic_table graphicRef65361 \" href=\"UTD.htm?19/18/19756\">",
"     table 3",
"    </a>",
"    ). In addition, primary prophylaxis can also be considered for patients with varices who are not considered to be at increased risk of hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H70835313\">",
"     'Primary prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56864681\">",
"    <span class=\"h1\">",
"     PRE-PRIMARY PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pre-primary prophylaxis aims to prevent the development of varices in patients with portal hypertension who have not yet developed varices. In such patients, treatment of the underling liver disease may help to prevent variceal development. However, treatment with nonselective beta blockers is not recommended because studies have failed to show a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 213 patients with portal hypertension but without esophageal varices were assigned to either receive the nonselective beta blocker",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"       timolol",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/6\">",
"       6",
"      </a>",
"      ]. The primary endpoint was the development of varices or variceal hemorrhage. After a median follow-up of 55 months, the primary endpoint was reached in 42 of 108 patients (39 percent) in the timolol group and in 42 of 105 patients (40 percent) in the placebo group (p=0.89). There was also no differences between the groups with regard to the development of ascites, need for liver transplantation, or death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients without varices should have routine screening endoscopies performed to detect the development of varices. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Screening for varices'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70835313\">",
"    <span class=\"h1\">",
"     PRIMARY PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis refers to the prevention of a first variceal hemorrhage in a patient with varices. Typically, one of two approaches is used for primary prophylaxis: pharmacologic prophylaxis using a nonselective beta blocker, or endoscopic prophylaxis using endoscopic variceal ligation (EVL). Both beta blockers and EVL are superior to no treatment for the prevention of a first variceal hemorrhage. Some data suggest that the risk of variceal hemorrhage may be lower with EVL compared with beta blockers, but there is no benefit with regard to mortality and EVL puts patients at risk for procedure-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Beta blockers, have a low risk of serious side effects, though many patients do not tolerate them. Beta blockers may also decrease the risk developing of ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/16\">",
"     16",
"    </a>",
"    ] or spontaneous bacterial peritonitis, possibly by reducing portal pressure and decreasing bacterial translocation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Nonselective beta blockers'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H750670\">",
"     'Endoscopic variceal ligation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our approach to primary prophylaxis is similar to approaches outlined in the Baveno V consensus guidelines and the American Association for the Study of Liver Diseases (AASLD) guidelines (see",
"    <a class=\"local\" href=\"#H747040\">",
"     'Guidelines'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. We give prophylaxis to patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small varices with red signs (",
"      <a class=\"graphic graphic_picture graphicRef50222 \" href=\"UTD.htm?7/25/7568\">",
"       picture 1",
"      </a>",
"      ) or Child B or C cirrhosis (",
"      <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Medium or large varices",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, we follow patients with Child A cirrhosis who have small varices without red signs with routine upper endoscopy to monitor for the development of red signs or for variceal enlargement. (See",
"    <a class=\"local\" href=\"#H747136\">",
"     'Patient follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our approach is to treat patients with small varices with red signs or Child B or C cirrhosis with a nonselective beta blocker. If the patient does not tolerate therapy with a beta blocker, we will treat with EVL.",
"   </p>",
"   <p>",
"    Typically, once a beta blocker is started, repeat upper endoscopy is not required. However, patients may undergo endoscopy for other reasons, and variceal enlargement may be seen in a patient who is receiving a beta blocker. The natural history of varices in this setting is not certain, and given the importance of variceal size in determining bleeding risk, it is our approach to ligate varices that have enlarged despite beta blocker therapy. However, this approach has not been studied in clinical trials and differs from the published guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link&amp;anchor=H129709551#H129709551\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\", section on 'Size of varices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with medium or large varices can be treated with either a nonselective beta blocker or EVL. The choice of a nonselective beta blocker or EVL depends upon whether the patient can tolerate a nonselective beta blocker and whether the patient is willing to accept the risks of EVL and undergo the multiple endoscopic procedures that are required. Because some data suggest EVL may be more effective than beta blockers in patients with large varices, our preference is to treat such patients with EVL when possible [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approaches to primary prophylaxis that are",
"    <strong>",
"     not",
"    </strong>",
"    recommended include nitrates (either alone or in combination with beta blockers), shunt therapy, or sclerotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In addition, combination therapy with beta blockers and EVL is not recommended for primary prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/3\">",
"     3",
"    </a>",
"    ]. However, prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    is a promising alternative that needs to be investigated further [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69669989\">",
"    <span class=\"h2\">",
"     Pharmacologic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy for primary prophylaxis for variceal hemorrhage is comprised primarily of nonselective beta blockers, though other agents have been studied. Nonselective beta blockers are typically used for patients with small varices and are the primary alternative to esophageal variceal band ligation for primary prophylaxis in patients with medium or large varices. (See",
"    <a class=\"local\" href=\"#H750670\">",
"     'Endoscopic variceal ligation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Nonselective beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of pharmacologic treatment is to decrease portal venous inflow. Nonselective beta blockers such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    block the adrenergic dilatory tone in mesenteric arterioles, resulting in unopposed alpha adrenergic mediated vasoconstriction and therefore a decrease in portal inflow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/18\">",
"     18",
"    </a>",
"    ]. These are the only drugs recommended for prophylaxis against a first variceal hemorrhage. However, the safety of nonselective beta blockers in patients with refractory ascites has been called into question. (See",
"    <a class=\"local\" href=\"#H21558131\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although cardioselective beta blockers such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    also reduce portal venous pressure, the effect is not dramatic, and their use remains to be validated in large scale clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H748332\">",
"    <span class=\"h4\">",
"     Dose titration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of the nonselective beta blocker can be titrated using either patient's heart rate or by measuring the hepatic venous pressure gradient (HVPG). The HVPG reflects the degree of portal decompression achieved by medical therapy but is an invasive procedure. Typically, we titrate the dose using the patient's heart rate, though in selective cases, HVPG-guided therapy may be used if expertise to accurately measure the HVPG is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157005752\">",
"    <span class=\"h5\">",
"     Resting heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;When titrating the dose of the nonselective beta blocker using the patient's heart rate, the drug is initiated at a low dose. The dose is then increased as needed to achieve a resting heart rate of about 55 to 60",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    (reflecting what is generally considered to be the maximal tolerated dose). If the pulse rate remains high despite large doses of beta blockers in a patients who is adherent to the medication, measurement of the HVPG following intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    can help differentiate patients who are unlikely to respond to beta blockers from those who need a higher dose or may be poorly adherent to their medication. An acute HVPG drop of 10 to 20 percent or to &le;12 mmHg following administration of intravenous propranolol is associated with a response to orally administered beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157005766\">",
"    <span class=\"h5\">",
"     Hepatic venous pressure gradient",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach for monitoring therapy and guiding adjustments in the dose of the nonselective beta blocker is to measure the HVPG. A reduction of the HVPG to below 12 mmHg virtually eliminates the risk of variceal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/9,21-27\">",
"     9,21-27",
"    </a>",
"    ]. However, the procedure is invasive, and the cost-effectiveness of HVPG measurement to guide medical therapy remains to be demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/28\">",
"     28",
"    </a>",
"    ]. As a result, HVPG measurement is not routinely used in most medical centers in the United States to guide therapy. However, the Baveno V consensus guidelines recommend routine HVPG measurements to monitor patients being treated with nonselective beta blockers if adequate resources and expertise are available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HVPG is calculated by subtracting the free hepatic venous pressure (which reflects intraabdominal pressure) from the wedged hepatic venous pressure (WHVP, which reflects portal venous pressure). These values are obtained by hepatic venous catheterization. The hepatic venous pressure is determined by direct measurement of pressure in the hepatic vein. The WHVP is obtained by either wedging the catheter in the end tributaries of a hepatic vein or by balloon occlusion of the hepatic vein.",
"   </p>",
"   <p>",
"    If HVPG monitoring is being used to guide therapy, the hemodynamic goal of treatment with a nonselective beta blocker is to decrease the HVPG by 20 percent or to &le;12 mmHg. Patients failing to meet these goals should have their beta blocker dose increased if tolerated. If a higher dose is not tolerated or a goal reduction in HVPG cannot be achieved, then EVL is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H747559\">",
"    <span class=\"h4\">",
"     Nadolol and propranolol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     Nadolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    are two nonselective beta blockers that are used for primary prophylaxis against variceal hemorrhage. We typically use nadolol (since it can be given once daily) at a starting dose of 40 mg per day. Propranolol is usually started at a dose of 20 mg twice a day. However, beta blockers may not be well tolerated in patients with severe vasodilation and systemic hypotension (mean arterial pressure &lt;85 mmHg). As a result, it may be prudent either to avoid beta blockers or to start with a lower dose (eg, 20 mg per day of nadolol) in such patients. Nadolol is renally excreted, and its starting dose has to be modified in response to renal insufficiency. In addition, beta blockers can decrease renal blood flow, so renal function should be monitored.",
"   </p>",
"   <p>",
"    Oral or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    produces a 9 to 23 percent decrease in the HVPG [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/18,29-32\">",
"     18,29-32",
"    </a>",
"    ]. This change is mostly due to a reduction in WHVP, which is primarily caused by decreased portal venous inflow secondary to mesenteric arteriolar constriction. At higher doses of propranolol, decreases in heart rate and cardiac output contribute to a further lowering of portal pressure by decreasing splanchnic blood flow. Propranolol also can prevent the rise in HVPG observed during moderate physical exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/33\">",
"     33",
"    </a>",
"    ]. Although tachyphylaxis to beta blockers can occur, propranolol maintains its portal hypotensive effects in most patients during long-term administration.",
"   </p>",
"   <p>",
"    The degree of portal decompression achievable by a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    is variable; up to 50 percent of subjects show a 10 percent or less decrease in HVPG [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The lack of response in some patients may be due to a concomitant rise in collateral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatic sinusoidal resistance, or a reflex increase in hepatic arterial flow. The latter mechanism preserves sinusoidal perfusion in the face of decreased portal venous inflow. Many nonresponders at an initial dose may respond to higher doses.",
"   </p>",
"   <p>",
"    Multiple randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    with placebo for primary prophylaxis against variceal hemorrhage have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/18,34-40\">",
"     18,34-40",
"    </a>",
"    ]. Comparison of these trials is complicated by considerable heterogeneity among the patient populations and drug doses used. However, studies have attempted to summarize the findings from multiple trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis that included seven trials with 797 patients found that patients treated with beta blockers had improved outcomes compared with controls [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/41\">",
"       41",
"      </a>",
"      ]. Patients treated with beta blockers had lower bleeding rates (12 versus 23 percent) and fewer deaths due to bleeding (5 versus 10 percent). There was also a trend toward a lower overall mortality rate (21 versus 27 percent, p=0.052).",
"     </li>",
"     <li>",
"      A second analysis concluded that in order to prevent one episode of bleeding, 11 patients would need to be treated with a nonselective beta blocker [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/7\">",
"       7",
"      </a>",
"      ]. That analysis also found a trend toward decreased mortality in patients treated with beta blockers (odds ratio 0.75; 95% confidence interval 0.57-1.06).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the subset of patients with small varices, treatment with a nonselective beta blocker reduces the likelihood of progression to large varices and decreases the cumulative probability of variceal hemorrhage in a placebo controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors associated with a decreased probability of nonselective beta blockers preventing variceal bleeding include younger patient age, large variceal size, advanced liver failure, and lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H747625\">",
"    <span class=\"h4\">",
"     Carvedilol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    , is a potent beta blocker that also has mild anti-alpha 1 adrenergic activity. It is a promising alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , but it is not yet recommended for routine prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition to reducing portal venous inflow through nonselective beta blockade, the anti-alpha 1 adrenergic activity leads to reduced hepatic vascular tone and hepatic resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/43\">",
"     43",
"    </a>",
"    ]. This in turn leads to a further reduction in portal pressure. However, it also can result in significant drops in mean arterial blood pressure (average decrease of 23 percent in one study), which may be poorly tolerated by patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies have examined the hemodynamic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    and suggest that carvedilol causes a dose-related decrease in HVPG of about 20 percent from baseline, which is significantly higher than is seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/44-54\">",
"     44-54",
"    </a>",
"    ]. As an example, one study with 35 patients with cirrhosis found that the mean decrease in HVPG with carvedilol was 20 percent, compared with 13 percent for propranolol [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, significantly more patients treated with carvedilol attained an HVPG &le;12 mmHg compared with propranolol (64 versus 14 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    has also been compared with EVL. In a randomized trial with 152 patient, carvedilol had lower rates of first variceal hemorrhage compared with EVL (10 versus 23 percent), and there was no difference in overall or hemorrhage-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition, six patients in the EVL group bled as a result of ulcers related to the banding.",
"   </p>",
"   <p>",
"    The effect on HVPG appears to be greater in patients with Child B or C cirrhosis compared with patients with Child A cirrhosis, possibly due to changes in hepatic metabolism of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/44,47\">",
"     44,47",
"    </a>",
"    ]. For patients with Child A cirrhosis, a dose of 12.5 mg twice a day has been recommended, whereas a dose of 6.25 mg twice a day has been recommended for patients with Child B or C cirrhosis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    does not decrease the glomerular filtration rate, but it is associated in with an increase in plasma volume. As a result, patients may require the addition of a diuretic or, for those already on a diuretic, an increase in the dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21558131\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are associated with numerous side effects. In patients with cirrhosis, clinically important adverse effects include bronchoconstriction, heart failure, and impotence. Beta blockers rarely induce liver failure from decreased portal blood flow because total hepatic blood flow is usually maintained by an increase in hepatic arterial flow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/55\">",
"     55",
"    </a>",
"    ]. Despite the inability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    to cross the blood brain barrier due to its hydrophilic nature (in contrast to the highly lipophilic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ), central nervous system side effects of the two medications do not differ. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The routine use of beta blockers in patients with cirrhosis and refractory ascites has been called into question. A prospective study of 151 patients with cirrhosis and refractory ascites found that median survival was significantly longer in patients who did not receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    versus those who did (20 versus 5 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/56\">",
"     56",
"    </a>",
"    ]. Independent predictors of mortality in that study were Child C cirrhosis, hyponatremia, refractory ascites due to renal failure, and beta blocker therapy.",
"   </p>",
"   <p>",
"    Whether the beta blockers accounted for the increased mortality is uncertain, since the study was not randomized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients who received beta blockers were more likely to have varices (100 versus 4 percent). There was also a trend toward a higher proportion of patients with Child C cirrhosis in the beta blocker group (74 versus 61 percent).",
"   </p>",
"   <p>",
"    It is important to note that beta blockers reduce cardiac output in cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/32\">",
"     32",
"    </a>",
"    ], which is a strong predictor of hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/58\">",
"     58",
"    </a>",
"    ]. A possible explanation for the increased mortality in the patients who received beta blockers was that the beta blockers may have precipitated hepatorenal syndrome. In addition, many of the patients died from complications related to",
"    <span class=\"nowrap\">",
"     sepsis/spontaneous",
"    </span>",
"    bacterial peritonitis. In such patients, the decreased cardiac output related to beta blockade may have compounded the hypotension related to vasodilation from sepsis.",
"   </p>",
"   <p>",
"    However, preliminary results from a second study suggest that beta blockers may not increase mortality in patients with ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/59\">",
"     59",
"    </a>",
"    ]. The retrospective study included 194 patients with decompensated cirrhosis and ascites who did not have a history of variceal hemorrhage. Varices were present in 132 patients (68 percent). Predictors of decreased survival included higher Child class (hazard ratio [HR] 1.2) and the presence of varices (HR 1.2). Beta blocker use was not associated with decreased survival. However, this study was not restricted to patients with refractory ascites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrates also decrease portal pressure in patients with cirrhosis, but they are not currently recommended for primary prophylaxis. Studies have had variable results with regard to whether nitrates decrease hemorrhage risk, and one study noted a possible increase in mortality among patients on nitrates. A meta-analysis of 10 studies failed to show a decrease in hemorrhage rate or mortality with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    compared with beta blockers or placebo when used for primary prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Combination pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for combination therapy with beta blockers and nitrates was based upon observations in animal models of portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/61\">",
"     61",
"    </a>",
"    ]. Beta blockers lead to unopposed alpha adrenergic activity, which increases splanchnic arterial pressure (thereby reducing portal pressure). However, increased alpha adrenergic pressure also causes increased portohepatic outflow resistance (which reduces the net benefit on portal pressure). The effect of beta blockade on portohepatic outflow resistance can be counteracted with nitrates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least three controlled trials have evaluated combination therapy with a beta blocker plus a nitrate with variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. A summary of these data (which included a total of 552 patients) suggested that combination therapy had no significant benefit in preventing first hemorrhage or reducing mortality compared with treatment with a beta blocker alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/65\">",
"     65",
"    </a>",
"    ]. The variability of the results of the individual trials can be seen in the two that have been published in final form [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial included 146 patients with varices who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      alone (40 to 160 mg per day, titrated to achieve a 20 to 25 percent decrease in resting heart rate) or nadolol plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"       isosorbide mononitrate",
"      </a>",
"      (10 mg twice daily increased to 20 mg unless hypotension or severe headache occurred) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/62\">",
"       62",
"      </a>",
"      ]. During 40 months of follow-up, the cumulative risk of variceal hemorrhage was significantly reduced in the combined therapy group (7.5 versus 18 percent). Furthermore, there was a statistically nonsignificant trend toward decreased mortality in the combined therapy group. Eight patients (11 percent) in the combined therapy group had to discontinue treatment due to adverse effects (mostly headache). Considering the absolute risk difference, approximately 10 patients would have to be treated with combination therapy to prevent one additional hemorrhage event in a patient receiving monotherapy with nadolol.",
"      <br/>",
"      <br/>",
"      Long-term follow-up in these patients (median 55 months) demonstrated a continued benefit in the patients randomized to combination therapy (cumulative risk of hemorrhage 29 versus 12 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/66\">",
"       66",
"      </a>",
"      ]. However, no difference in survival was observed between the two groups.",
"     </li>",
"     <li>",
"      A second trial focused on 349 patients who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"       isosorbide mononitrate",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/63\">",
"       63",
"      </a>",
"      ]. No significant differences were observed in the one- and two-year probabilities of variceal hemorrhage between those treated with combination therapy or those treated with propranolol alone (5 versus 8 percent and 13 versus 11 percent, respectively). The only independent predictor of hemorrhage was variceal size.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several possible explanations for the different results, leaving some enthusiasm for continued investigation in this area [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/67\">",
"     67",
"    </a>",
"    ]. The first study only included patients with medium to large varices, whereas the second included patients with varices of any size. This difference may have contributed to the markedly different hemorrhage rates in the control arms of the studies (18 versus 8 percent), and could suggest that the second study was underpowered to detect a benefit.",
"   </p>",
"   <p>",
"    In another report, the majority of patients who responded to combination therapy (defined by a reduction in the HVPG) appeared to have a durable benefit for up to 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other drugs are being evaluated for the treatment of portal hypertension. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , molsidomine (a nitric oxide releasing compound),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    (an angiotensin II receptor antagonist). A potential benefit for angiotensin II receptor antagonists was suggested in a pilot study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/69\">",
"     69",
"    </a>",
"    ] but not confirmed in at least three subsequent randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     Simvastatin",
"    </a>",
"    increases hepatic generation of nitric oxide and has been shown to decrease the HVPG in patients with cirrhosis without affecting systemic hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. A randomized trial compared simvastatin with placebo in 59 patients with cirrhosis and portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/73\">",
"     73",
"    </a>",
"    ]. Patients were assigned to either simvastatin 20 mg per day (increasing to 40 mg after 15 days) or placebo for one month. The mean decrease in HVPG among those treated with simvastatin was 8 percent, whereas there was no decrease in those who received placebo. In addition, the effects were additive with those from beta blockers. Additional studies with longer-term follow-up are needed to clarify the potential role for simvastatin in patients with portal hypertension from cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70834674\">",
"    <span class=\"h2\">",
"     Endoscopic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic variceal ligation (EVL) is an alternative to nonselective beta blockers for primary prophylaxis against variceal hemorrhage. It is typically used for patients with medium or large varices who are intolerant of or have contraindications to beta blocker therapy. (See",
"    <a class=\"local\" href=\"#H70835313\">",
"     'Primary prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H750670\">",
"    <span class=\"h3\">",
"     Endoscopic variceal ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;EVL eradicates esophageal varices with fewer complications than endoscopic sclerotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/75\">",
"     75",
"    </a>",
"    ]. However, EVL has been associated with significant complications, including hemorrhage from banding-induced ulcerations. Because of the potential complications associated with EVL, the procedure should be performed by endoscopists with expertise in prophylactic banding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"     \"Endoscopic variceal ligation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EVL has been evaluated as primary prophylaxis for the prevention of variceal hemorrhage in patients with medium to large varices in several trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/76-83\">",
"     76-83",
"    </a>",
"    ]. Trials that compared EVL with beta blockers have had variable results. Some show a decreased risk of hemorrhage with EVL, while others do not. Several meta-analyses have also been published [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/14,84-87\">",
"     14,84-87",
"    </a>",
"    ]. Overall, the data suggest that EVL is effective for primary prophylaxis and similar to beta blockers overall, with somewhat less hemorrhage but no changes in overall mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis that included a total of 601 patients from five trials comparing prophylactic EVL with untreated controls found that prophylactic EVL decreased the risk of first variceal hemorrhage (relative risk [RR] 0.36), hemorrhage-related mortality (RR 0.20), and all-cause mortality (RR 0.55) compared with no treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis that included 1023 patients compared prophylactic EVL with beta blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/14\">",
"       14",
"      </a>",
"      ]. The analysis found that there was no difference between the treatments with regard to gastrointestinal hemorrhage (RR 0.79), all-cause mortality (RR 1.06), or hemorrhage-related mortality (RR 0.66). While there was a decrease in variceal hemorrhage with EVL compared with beta blockers (RR 0.72; 95% CI 0.4 to 0.96), variceal hemorrhage was not significantly different between the two groups when only high-quality trials were considered (RR 0.84; 95% CI 0.60 to 1.17).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether there is a benefit from adding beta blockers in patients who have undergone EVL for primary prophylaxis has not been well studied. In one randomized trial with 144 patients with high-risk varices, combination therapy was not more effective than EVL alone in preventing hemorrhage or death [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/88\">",
"     88",
"    </a>",
"    ]. However, patients receiving combination therapy were less likely to develop recurrent varices. Conversely, there does not appear to be a benefit from adding EVL to beta blocker therapy. This was demonstrated in a trial that included 140 patients who were assigned to either combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    plus EVL or nadolol monotherapy. Combination therapy was not more effective than nadolol alone in preventing a first variceal bleed, though patients in the nadolol monotherapy arm had fewer adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The expense, inconvenience, and risk of EVL compared with beta blockers are additional factors that must be considered in choosing EVL as primary therapy. An economic analysis found that its cost-effectiveness (compared with beta blockers) depended upon whether quality of life was considered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/90\">",
"     90",
"    </a>",
"    ]. In a model that considered quality of life to be superior with EVL compared with beta blockers, EVL was cost-effective. By contrast, EVL was not cost-effective when considering life-years gained alone. Assessing comparative quality of life in these settings is not straightforward and hence the validity of this observation remains unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another consideration is that EVL may not be a permanent solution since varices can recur after initial eradication. In one study, for example, varices recurred in 22 percent of patients (on average four months after initial therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/77\">",
"     77",
"    </a>",
"    ]. Because of this, patients treated with EVL require routine endoscopic surveillance. (See",
"    <a class=\"local\" href=\"#H747136\">",
"     'Patient follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21559740\">",
"    <span class=\"h3\">",
"     Cyanoacrylate injection of gastric varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanoacrylate injection is not recommended for primary prophylaxis against variceal hemorrhage, though it has been studied for this use in patients with large gastric varices. A randomized trial of patients with gastric varices assigned patients to treatment with cyanoacrylate injection, beta blockers, or no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/91\">",
"     91",
"    </a>",
"    ]. Patients were followed for a median of 26 months. The actuarial probability of hemorrhage from gastric varices was significantly lower among patients treated with cyanoacrylate injection compared with those treated with beta blockers or no treatment (13 versus 28 and 45 percent, respectively). In addition, the actuarial probability of survival was higher in the cyanoacrylate group compared with the no-treatment group (90 versus 72 percent).",
"   </p>",
"   <p>",
"    Cyanoacrylate injection has been associated with procedural, septic, and embolic complications, and its role has yet to be established. While the Baveno consensus guidelines recommend cyanoacrylate injection for the treatment of acute hemorrhage from gastric varices, it is not recommended for primary prophylaxis. In addition, cyanoacrylate has not been approved by the US Food and Drug Administration for endoscopic use, though it has been approved in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/92\">",
"     92",
"    </a>",
"    ]. For the time being, patients with gastric varices should continue to receive beta blockers for primary prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of active variceal hemorrhage\", section on 'Gastric varices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70834689\">",
"    <span class=\"h2\">",
"     Approaches that are not recommended",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic sclerotherapy, surgical shunts, and transjugular intrahepatic portosystemic shunts (TIPS) have been proposed for primary prophylaxis against variceal hemorrhage. However, the available data do not support their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21560389\">",
"    <span class=\"h3\">",
"     Endoscopic sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerotherapy is an effective treatment for bleeding esophageal varices. This observation led to a large number of prospective randomized controlled trials to examine the value of endoscopic sclerotherapy versus nonspecific medical treatment for primary prophylaxis of variceal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/93\">",
"     93",
"    </a>",
"    ]. While initial trials suggested a possible benefit of sclerotherapy for primary prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/94-96\">",
"     94-96",
"    </a>",
"    ], subsequent trials failed to confirm a benefit compared with either sham therapy or nonselective beta blocker use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/36,37,97,98\">",
"     36,37,97,98",
"    </a>",
"    ]. As a result, sclerotherapy",
"    <strong>",
"     is not",
"    </strong>",
"    recommended for the primary prophylaxis of variceal hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Surgical portal decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials comparing surgical portacaval shunts to medical therapy were carried out in the late",
"    <span class=\"nowrap\">",
"     1960s/early",
"    </span>",
"    1970s. These studies found that while surgery was highly effective in preventing variceal hemorrhage, this benefit was offset by the high incidence of crippling encephalopathy after portacaval shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. In addition, these studies demonstrated a survival benefit for patients treated medically. Thus, portacaval shunts have been abandoned for primary prophylaxis of variceal hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Transjugular intrahepatic portosystemic shunts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinusoidal and portal decompression can be achieved with TIPS without the risks of general anesthesia (",
"    <a class=\"graphic graphic_figure graphicRef72311 \" href=\"UTD.htm?3/10/3239\">",
"     figure 1",
"    </a>",
"    ). This has led to a resurgence of interest in mechanical portal decompression as a treatment of portal hypertension. However, there are no data to support the use of TIPS for primary prophylaxis of variceal hemorrhage. In the absence of evidence of benefit and in light of the significant complications associated with TIPS (eg, hepatic encephalopathy), TIPS should",
"    <strong>",
"     not",
"    </strong>",
"    be used for primary prophylaxis of variceal hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=see_link\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H747136\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with small varices who are not being treated with nonselective beta blockers should undergo repeat upper endoscopy every two years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/2\">",
"     2",
"    </a>",
"    ]. If red signs develop or if the varices increase in size, prophylactic treatment should be initiated. If there is evidence of hepatic decompensation, upper endoscopy should be done at that time and repeated annually.",
"   </p>",
"   <p>",
"    In patients with small varices who receive beta blockers, guidelines do not recommend routine follow-up upper endoscopy. However, for patients with small varices and a history of hepatic decompensation who do not receive a beta blocker, upper endoscopy should be performed annually.",
"   </p>",
"   <p>",
"    However, because some patients with small varices will have variceal enlargement while being treated with beta blockers, our practice is to repeat an upper endoscopy in one to two years. If there is variceal enlargement, we then switch to EVL. Patients with medium or large varices who are receiving nonselective beta blockers do not require follow-up endoscopy unless there is evidence of hemorrhage. (See",
"    <a class=\"local\" href=\"#H70835313\">",
"     'Primary prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients treated with endoscopic variceal ligation should undergo upper endoscopy with banding every one to two weeks until the varices are obliterated. The first surveillance upper endoscopy is performed one to three months after obliteration and then every 6 to 12 months to check for variceal recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/49/27418/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/40/8834?source=see_link\">",
"       \"Patient information: Esophageal varices (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/9/12434?source=see_link\">",
"       \"Patient information: Screening for esophageal varices (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with cirrhosis should undergo diagnostic endoscopy to document the presence or absence of varices and to determine their risk for variceal hemorrhage. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Screening for varices'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link&amp;anchor=H21#H21\">",
"       \"Overview of the complications, prognosis, and management of cirrhosis\", section on 'Variceal bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with small varices with red signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Child B or C cirrhosis and for all patients with medium or large varices, we recommend prophylactic treatment rather than expectant management (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with Child A cirrhosis who have small varices without red signs, we suggest expectant management with routine upper endoscopy to monitor for the development of red signs or for variceal enlargement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H70835313\">",
"       'Primary prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link&amp;anchor=H129709535#H129709535\">",
"       \"Prediction of variceal hemorrhage in patients with cirrhosis\", section on 'Predictive factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with small varices with red signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Child B or C cirrhosis, we suggest treatment with a nonselective beta blocker rather than esophageal variceal ligation (EVL) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Studies have shown that treatment of patients with small varices with nonselective beta blockers reduces the likelihood of progression to large varices and decreases the probability of a first variceal hemorrhage. Data are lacking regarding the use of EVL for primary prophylaxis in patients with small varices. However, treatment with variceal ligation is a reasonable alternative if the patient does not",
"      <span class=\"nowrap\">",
"       tolerate/has",
"      </span>",
"      a contraindication to therapy with a beta blocker, in patients with refractory ascites, or if there is variceal enlargement despite treatment with a beta blocker. (See",
"      <a class=\"local\" href=\"#H747559\">",
"       'Nadolol and propranolol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with medium varices, we suggest treatment with either a nonselective beta blocker or EVL (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Both treatments have been shown to be effective in such patients. The choice of a nonselective beta blocker or EVL depends upon whether the patient can tolerate a nonselective beta blocker, whether a provider with expertise in EVL is available, and whether the patient is willing to accept the risks of EVL and undergo the multiple endoscopic procedures that are required. (See",
"      <a class=\"local\" href=\"#H70835313\">",
"       'Primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with large varices, we suggest treatment with EVL rather than a nonselective beta blocker (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Some data suggest EVL may be more effective than beta blockers in patients with large varices. Treatment with a nonselective beta blocker is a reasonable alternative in patients who are unwilling to accept the risks of EVL or undergo multiple endoscopic procedures for treatment or if a provider experienced in EVL is not available. (See",
"      <a class=\"local\" href=\"#H750670\">",
"       'Endoscopic variceal ligation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients being treated with nonselective beta blockers, we typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      (since it can be given once daily), starting with a dose of 40 mg per day. We then titrate the dose based upon the patient's hemodynamic response. (See",
"      <a class=\"local\" href=\"#H748332\">",
"       'Dose titration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hemodynamic goal of treatment with a nonselective beta blocker is to decrease the hepatic venous pressure gradient (HVPG) by 20 percent or to &le;12 mmHg. If the HVPG is not being used to monitor treatment, the dose of the beta blocker may instead be titrated to achieve a resting heart rate of about 55 to 60",
"      <span class=\"nowrap\">",
"       beats/minute",
"      </span>",
"      (reflecting what is generally considered to be the maximal tolerated dose). (See",
"      <a class=\"local\" href=\"#H748332\">",
"       'Dose titration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients, especially those with decompensated cirrhosis (Child B or C), who are receiving beta blockers should be monitored closely for side effects. Beta blockers may need to be stopped if intolerable side effects develop, including ascites that becomes refractory to treatment or worsening hepatic encephalopathy. (See",
"      <a class=\"local\" href=\"#H21558131\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approaches to primary prophylaxis that are not effective or are associated with high complication rates include nitrates (either alone or in combination with beta blockers), surgical shunts, or endoscopic sclerotherapy. In addition, performing EVL in patients already receiving nonselective beta blockers does not appear to improve outcomes. (See",
"      <a class=\"local\" href=\"#H70835313\">",
"       'Primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/1\">",
"      North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988; 319:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/2\">",
"      Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/3\">",
"      de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/4\">",
"      Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998; 28:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/5\">",
"      Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/6\">",
"      Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/7\">",
"      Vlachogiannakos J, Goulis J, Patch D, Burroughs AK. Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis. Aliment Pharmacol Ther 2000; 14:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/8\">",
"      Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982; 82:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/9\">",
"      D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/10\">",
"      Chalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol 2003; 98:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/11\">",
"      El-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000; 95:3566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/12\">",
"      Gana JC, Turner D, Mieli-Vergani G, et al. A clinical prediction rule and platelet count predict esophageal varices in children. Gastroenterology 2011; 141:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/13\">",
"      Beppu K, Inokuchi K, Koyanagi N, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 1981; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/14\">",
"      Li L, Yu C, Li Y. Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis. Can J Gastroenterol 2011; 25:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/15\">",
"      Triantos CK, Burroughs AK. Prevention of the development of varices and first portal hypertensive bleeding episode. Best Pract Res Clin Gastroenterol 2007; 21:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/16\">",
"      Hern&aacute;ndez-Gea V, Aracil C, Colomo A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with &beta;-blockers. Am J Gastroenterol 2012; 107:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/17\">",
"      Senzolo M, Cholongitas E, Burra P, et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/18\">",
"      Sanyal AJ, Shiffman ML. The pharmacologic treatment of portal hypertension. Annu Rev Gastrointest Pharmacol 1996; :242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/19\">",
"      de-Madaria E, Palaz&oacute;n JM, Hern&aacute;ndez FT, et al. Acute and chronic hemodynamic changes after propranolol in patients with cirrhosis under primary and secondary prophylaxis of variceal bleeding: a pilot study. Eur J Gastroenterol Hepatol 2010; 22:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/20\">",
"      Villanueva C, Aracil C, Colomo A, et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 2009; 137:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/21\">",
"      Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/22\">",
"      Sacerdoti D, Merkel C, Gatta A. Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. J Hepatol 1991; 12:124.",
"     </a>",
"    </li>",
"    <li>",
"     Ferayorni L, Polio J, Groszmann RJ. Drug therapy for portal hypertension: A five year review. In: Portal Hypertension II: Proceedings of the second Baveno International workshop on definitions, methodology and therapeutic strategies, de Franchis R (Ed), Blackwell Science, Oxford 1996. p.68.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/24\">",
"      Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/25\">",
"      Grace ND, Groszmann RJ, Garcia-Tsao G, et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998; 28:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/26\">",
"      Bureau C, P&eacute;ron JM, Alric L, et al. \"A La Carte\" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002; 36:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/27\">",
"      Albillos A, Ba&ntilde;ares R, Gonz&aacute;lez M, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007; 102:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/28\">",
"      Sanyal AJ. Hepatic venous pressure gradient: to measure or not to measure, that is the question. Hepatology 2000; 32:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/29\">",
"      Lebrec D, Hillon P, Mu��oz C, et al. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982; 2:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/30\">",
"      Bosch J, Masti R, Kravetz D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/31\">",
"      Garcia-Tsao G, Grace ND, Groszmann RJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 6:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/32\">",
"      Bendtsen F, Henriksen JH, S&oslash;rensen TI. Long-term effects of oral propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis and oesophageal varices. Scand J Gastroenterol 1991; 26:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/33\">",
"      Bandi JC, Garc&iacute;a-Pag&aacute;n JC, Escorsell A, et al. Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. Hepatology 1998; 28:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/34\">",
"      Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987; 317:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/35\">",
"      Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. J Hepatol 1989; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/36\">",
"      Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. The PROVA Study Group. Hepatology 1991; 14:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/37\">",
"      Andreani T, Poupon RE, Balkau BJ, et al. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology 1990; 12:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/38\">",
"      Id&eacute;o G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Hepatology 1988; 8:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/39\">",
"      Lebrec D, Poynard T, Capron JP, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. J Hepatol 1988; 7:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/40\">",
"      Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/41\">",
"      Hayes PC, Davis JM, Lewis JA, Bouchier IA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990; 336:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/42\">",
"      Cal&egrave;s P. Factors associated with failure of propranolol for the prevention of first bleeding in cirrhotic patients. The Study Group of Primary Prophylaxis. Gastroenterol Clin Biol 1992; 16:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/43\">",
"      Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 2010; 51:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/44\">",
"      Ba&ntilde;ares R, Moitinho E, Piqueras B, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999; 30:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/45\">",
"      Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009; 50:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/46\">",
"      Reiberger T, Ulbrich G, Ferlitsch A, et, al. Carvedilol for prophylaxis of variceal bleeding in cirrhotic patients with hemodynamic nonresponse to propranolol. Hepatology 2010; 52:329A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/47\">",
"      Ba&ntilde;ares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002; 36:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/48\">",
"      Hemstreet BA. Evaluation of carvedilol for the treatment of portal hypertension. Pharmacotherapy 2004; 24:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/49\">",
"      Tripathi D, Therapondos G, Lui HF, et al. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 2002; 16:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/50\">",
"      Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999; 30:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/51\">",
"      Lin HC, Yang YY, Hou MC, et al. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol 2004; 99:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/52\">",
"      Forrest EH, Bouchier IA, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol 1996; 25:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/53\">",
"      De BK, Das D, Sen S, et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol 2002; 17:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/54\">",
"      Bruha R, Vitek L, Petrtyl J, et al. Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. Scand J Gastroenterol 2006; 41:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/55\">",
"      Koshy A, Girod C, Lee SS, et al. Discrepancy between portal pressure and systemic hemodynamic changes after incremental doses of propranolol in awake portal hypertensive rats. Hepatology 1989; 9:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/56\">",
"      Serst&eacute; T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/57\">",
"      Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatology 2010; 52:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/58\">",
"      Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/59\">",
"      Zipprich A, Garcia-Tsao G, Seufferlein T, et al. The presence of esophageal varices (EV), but not treatement with beta-blockers, is associated with a poorer survival in patients with cirrhosis and ascites. Hepatology 2011; 54:461A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/60\">",
"      Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. Aliment Pharmacol Ther 2010; 32:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/61\">",
"      Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985; 5:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/62\">",
"      Merkel C, Marin R, Enzo E, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP). Lancet 1996; 348:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/63\">",
"      Garc&iacute;a-Pag&aacute;n JC, Morillas R, Ba&ntilde;ares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003; 37:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/64\">",
"      D'Amico G, Pasta L, Patti R, et al. Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of first bleeding in cirrhosis: A double-blind, placebo-controlled randomized trial (abstract). J Hepatol 2002; 30:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/65\">",
"      D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/66\">",
"      Merkel C, Marin R, Sacerdoti D, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 31:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/67\">",
"      Merkel C. Nonselective beta-blockers plus nitrates in portal hypertension: an open question. Hepatology 2003; 37:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/68\">",
"      Villanueva C, L&oacute;pez-Balaguer JM, Aracil C, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004; 40:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/69\">",
"      Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/70\">",
"      Gonz&aacute;lez-Abraldes J, Albillos A, Ba&ntilde;ares R, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/71\">",
"      Schepke M, Werner E, Biecker E, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/72\">",
"      Schepke M, Wiest R, Flacke S, et al. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study. Am J Gastroenterol 2008; 103:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/73\">",
"      Abraldes JG, Albillos A, Ba&ntilde;ares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/74\">",
"      Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/75\">",
"      Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992; 326:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/76\">",
"      Lay CS, Tsai YT, Teg CY, et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology 1997; 25:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/77\">",
"      Sarin SK, Lamba GS, Kumar M, et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/78\">",
"      Lo GH, Lai KH, Cheng JS, et al. Prophylactic banding ligation of high-risk esophageal varices in patients with cirrhosis: a prospective, randomized trial. J Hepatol 1999; 31:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/79\">",
"      Lui HF, Stanley AJ, Forrest EH, et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002; 123:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/80\">",
"      Lo GH, Chen WC, Chen MH, et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 2004; 59:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/81\">",
"      Schepke M, Kleber G, N&uuml;rnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004; 40:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/82\">",
"      Drastich P, Lata J, Petrtyl J, et al. Endoscopic variceal band ligation compared with propranolol for prophylaxis of first variceal bleeding. Ann Hepatol 2011; 10:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/83\">",
"      P&eacute;rez-Ayuso RM, Valderrama S, Espinoza M, et al. Endoscopic band ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhotic patients with high risk esophageal varices. Ann Hepatol 2010; 9:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/84\">",
"      Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001; 33:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/85\">",
"      Khuroo MS, Khuroo NS, Farahat KL, et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005; 21:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/86\">",
"      Gluud LL, Klingenberg S, Nikolova D, Gluud C. Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol 2007; 102:2842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/87\">",
"      Gluud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 2012; 8:CD004544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/88\">",
"      Sarin SK, Wadhawan M, Agarwal SR, et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 2005; 100:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/89\">",
"      Lo GH, Chen WC, Wang HM, Lee CC. Controlled trial of ligation plus nadolol versus nadolol alone for the prevention of first variceal bleeding. Hepatology 2010; 52:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/90\">",
"      Imperiale TF, Klein RW, Chalasani N. Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. Hepatology 2007; 45:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/91\">",
"      Mishra SR, Sharma BC, Kumar A, Sarin SK. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol 2011; 54:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/92\">",
"      Tissue Adhesives: A Review. Techniques in Gastrointestinal Endoscopy 2006; 8:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/93\">",
"      Pagliaro L, D'Amico G, S&ouml;rensen TI, et al. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992; 117:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/94\">",
"      Paquet KJ. Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices -- a prospective controlled randomized trial. Endoscopy 1982; 14:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/95\">",
"      Witzel L, Wolbergs E, Merki H. Prophylactic endoscopic sclerotherapy of oesophageal varices. A prospective controlled study. Lancet 1985; 1:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/96\">",
"      Piai G, Cipolletta L, Claar M, et al. Prophylactic sclerotherapy of high-risk esophageal varices: results of a multicentric prospective controlled trial. Hepatology 1988; 8:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/97\">",
"      Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized, single-blind, multicenter clinical trial. The Veterans Affairs Cooperative Variceal Sclerotherapy Group. N Engl J Med 1991; 324:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/98\">",
"      Avgerinos A, Armonis A, Manolakopoulos S, et al. Endoscopic sclerotherapy plus propranolol versus propranolol alone in the primary prevention of bleeding in high risk cirrhotic patients with esophageal varices: a prospective multicenter randomized trial. Gastrointest Endosc 2000; 51:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/99\">",
"      Resnick RH, Chalmers TC, Ishihara AM, et al. A controlled study of the prophylactic portacaval shunt. A final report. Ann Intern Med 1969; 70:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/100\">",
"      Conn HO, Lindenmuth WW, May CJ, Ramsby GR. Prophylactic portacaval anastomosis. Medicine (Baltimore) 1972; 51:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/49/27418/abstract/101\">",
"      Jackson FC, Perrin EB, Felix WR, Smith AG. A clinical investigation of the portacaval shunt. V. Survival analysis of the therapeutic operation. Ann Surg 1971; 174:672.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1245 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27418=[""].join("\n");
var outline_f26_49_27418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H747040\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PORTAL HEMODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SCREENING FOR VARICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H157005252\">",
"      Rationale behind screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H157005347\">",
"      Screening methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56864681\">",
"      PRE-PRIMARY PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70835313\">",
"      PRIMARY PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69669989\">",
"      Pharmacologic approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Nonselective beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H748332\">",
"      Dose titration",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H157005752\">",
"      - Resting heart rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H157005766\">",
"      - Hepatic venous pressure gradient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H747559\">",
"      Nadolol and propranolol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H747625\">",
"      Carvedilol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21558131\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Nitrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Combination pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70834674\">",
"      Endoscopic approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H750670\">",
"      - Endoscopic variceal ligation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21559740\">",
"      - Cyanoacrylate injection of gastric varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70834689\">",
"      Approaches that are not recommended",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21560389\">",
"      - Endoscopic sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Surgical portal decompression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H747136\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1245\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1245|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/10/3239\" title=\"figure 1\">",
"      Transjugular intrahepatic portosystemic shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1245|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/25/7568\" title=\"picture 1\">",
"      Red wale Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/51/43838\" title=\"picture 2\">",
"      Size classification of varices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1245|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/56/907\" title=\"table 2\">",
"      Complications of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/18/19756\" title=\"table 3\">",
"      Probability bleeding varices",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=related_link\">",
"      Complications of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=related_link\">",
"      Endoscopic variceal ligation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/40/8834?source=related_link\">",
"      Patient information: Esophageal varices (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/9/12434?source=related_link\">",
"      Patient information: Screening for esophageal varices (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=related_link\">",
"      Prediction of variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=related_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_49_27419="Mammalian tissues expressing gastrin";
var content_f26_49_27419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mammalian tissues expressing gastrin and its metabolite intermediates (progastrin, glycine extended derivatives and gastrin)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric antrum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jejunum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ileum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Genital tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovaries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testicles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spermatoza",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurodendocrine tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebellum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vagus nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothalamus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal medulla",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respiratory tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchial mucosa",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Rehfeld JF, Physiologic Reviews, 1998; 74:1087.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27419=[""].join("\n");
var outline_f26_49_27419=null;
var title_f26_49_27420="Resuscitative measures for category II and III FHR tracings";
var content_f26_49_27420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Various intrauterine resuscitative measures for Category II and/or III tracings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Goal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated FHR abnormality*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential intervention(s)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Promote fetal oxygenation and improve uteroplacental blood flow",
"       </td>",
"       <td rowspan=\"4\">",
"        <ul>",
"         <li>",
"          Recurrent late decelerations",
"         </li>",
"         <li>",
"          Prolonged decelerations or bradycardia",
"         </li>",
"         <li>",
"          Minimal or absent FHR variability",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Place mother in a lateral position (either left or right)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give IV fluid bolus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce uterine contraction frequency",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Reduce uterine activity",
"       </td>",
"       <td rowspan=\"2\">",
"        <ul>",
"         <li>",
"          Tachysystole with Category II or III tracing",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Discontinue oxytocin or cervical ripening agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer tocolytic medication (eg, terbutaline)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Alleviate umbilical cord compression",
"       </td>",
"       <td rowspan=\"3\">",
"        <ul>",
"         <li>",
"          Recurrent variable decelerations",
"         </li>",
"         <li>",
"          Prolonged decelerations or bradycardia",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Reposition mother (left or right lateral, hands and knees)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform amnioinfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If umbilical cord prolapse is noted, elevate the presenting fetal part while preparing for operative delivery",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Evaluation for the underlying suspected cause(s) is also an important step in management of abnormal FHR tracings.",
"     <br/>",
"     &Delta; Depending on the suspected underlying cause(s) of FHR abnormality, combining multiple interventions simultaneously may be appropriate and potentially more effective than doing individually or serially.",
"     <sup>",
"      [1]",
"     </sup>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Simpson KR, James DC. Efficacy of intrauterine resuscitation techniques in improving fetal oxygen status during labor. Obstet Gynecol 2005; 105:1362.",
"      </li>",
"     </ol>",
"     <br/>",
"     Modified and reproduced with permission from: ACOG Practice Bulletin #116. Management of intrapartum fetal heart rate tracings. Obstet Gynecol 2010; 116:1232. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27420=[""].join("\n");
var outline_f26_49_27420=null;
var title_f26_49_27421="Chest wall impact VF";
var content_f26_49_27421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Chest wall trauma causes ventricular fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 225px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Differences in the frequency with which ventricular fibrillation resulted from chest-wall impact at 30 miles per hour during the period of cardiac cycle vulnerable to induction of ventricular fibrillation, ie, from 30 to 15 msec before T-wave peak.",
"    <div class=\"footnotes\">",
"     * p&lt;0.03 for the differences between regulation baseball and very soft baseball.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      p&lt;0.01 for the differences between wooden object and each type of baseball.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Link MS, Wang PJ, Pandian NG, et al. N Engl J Med 1998; 338:1805.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27421=[""].join("\n");
var outline_f26_49_27421=null;
var title_f26_49_27422="Patients review";
var content_f26_49_27422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient's review",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Dimension of care",
"       </td>",
"       <td class=\"subtitle1\">",
"        Focus of a patient's review",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggestions for practice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respect for patients' values, preferences, and expressed needs",
"       </td>",
"       <td>",
"        <p>",
"         What are the patient's short-term and long-term goals?",
"        </p>",
"        <p>",
"         What level of involvement does the patient want in decision making?",
"        </p>",
"        <p>",
"         What does the patient need, want, or expect from the clinician and the visit?",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Learn about, and educate staff about, the health beliefs, practices, and mores of specific ethnic and cultural groups in your patient population.",
"        </p>",
"        <p>",
"         Use clinical interview protocols that elicit patients' perceptions about their illness and their expectations of treatment.",
"        </p>",
"        <p>",
"         Develop culturally appropriate standards for staff behavior with patients (for example, forms of address, rules of propriety).",
"        </p>",
"        <p>",
"         Ask, don't assume: Ask patients what they want to know; suggest questions that patients might have; ask patients if they understand.",
"        </p>",
"        <p>",
"         Ask, don't assume, how therapeutic decisions affect patients' lives, what patients' preferences would be among alternative treatments and outcomes.",
"        </p>",
"        <p>",
"         Negotiate therapeutic strategies with patients.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coordination of care and integration of services within a clinical setting",
"       </td>",
"       <td>",
"        <p>",
"         Is care delivered by a range of providers effectively coordinated?",
"        </p>",
"        <p>",
"         Does the patient get consistent information from different clinicians?",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Give patients written and/or visual information identifying members of the clinical team, explaining the role of each, and make sure they know who is in charge of their care.",
"        </p>",
"        <p>",
"         Identify one person on the clinical team to serve as the primary conduit of information for the patient and his family.",
"        </p>",
"        <p>",
"         Find out about patients' experiences with clinical tests and procedures (for example, about waiting times, delays, pain or discomfort, and the information they were given).",
"        </p>",
"        <p>",
"         Give patients and their families realistic expectations about waiting times, levels of discomfort, possible side effects, and other factors relating to tests and procedures.",
"        </p>",
"        <p>",
"         Make sure that staff who come in contact with the patients have the responsibility, ability, and information to get patients what they want or need.",
"        </p>",
"        <p>",
"         Give all staff who come in regular contact with patients information about special needs, activity restrictions, and other appropriate information.",
"        </p>",
"        <p>",
"         Encourage staff at all levels to help patients solve their problems, and reward them for doing so.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Communication between patient and providers; dissemination of accurate, timely, and appropriate information; and education about the long-term implications of disease and illness",
"       </td>",
"       <td>",
"        <p>",
"         Does the patient have the information he or she wants about clinical status, diagnostic tests, and treatment options?",
"        </p>",
"        <p>",
"         Do the patient and family know what they need to know to manage on their own to the extent they are able to do so?",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Establish explicit procedures that give patients ready access to knowledgeable healthcare professionals who can answer questions and give them help. Make sure patients understand and can follow these procedures.",
"        </p>",
"        <p>",
"         Clarify the goals of patient and provider.",
"        </p>",
"        <p>",
"         Consider giving patients access to their medical records; encourage questions; invite families and patients to write their goals for treatment in the record.",
"        </p>",
"        <p>",
"         Make communication a regular topic of staff meetings; use videotapes of real patient interactions to initiate discussion.",
"        </p>",
"        <p>",
"         Help patients learn negotiation strategies that can \"empower\" them in discussions with doctors and nurses.",
"        </p>",
"        <p>",
"         Encourage the patient and family to write down their questions and concerns.",
"        </p>",
"        <p>",
"         Learn about, and educate staff about, the typical communication needs and patterns of the socio-demographic and cultural groups seen in your practice. Use these to heighten awareness of the differences among patients, rather than to reinforce stereotypes.",
"        </p>",
"        <p>",
"         Identify staff members who have particular skill in translating \"technical\" language into \"everyday\" language and use them to help improve communication.",
"        </p>",
"        <p>",
"         Tape record important conversations with patients and give them a copy of the tape to listen to later with their families. Encourage them to return with questions or confusion they had after listening to the tapes.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enhancing physical comfort",
"       </td>",
"       <td>",
"        <p>",
"         Is pain alleviated as much as possible?",
"        </p>",
"        <p>",
"         Does the patient have the help he or she needs with bathing, eating, household chores, or other activities of daily living?",
"        </p>",
"        <p>",
"         Have remediable deficits in functional status been adequately addressed?",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Help patients who experience pain communicate about it by asking them to rate the intensity of their pain on a scale of one to ten.",
"        </p>",
"        <p>",
"         Record patients' pain status along with other vital signs.",
"        </p>",
"        <p>",
"         Educate all clinical staff about appropriate pain control protocols; discuss misconceptions about narcotics and their true risks and benefits.",
"        </p>",
"        <p>",
"         Assess patients' functional status and available sources of support.",
"        </p>",
"        <p>",
"         Designate staff to get patients the help they need and reward them for doing so.",
"        </p>",
"        <p>",
"         Use natural and incandescent lighting wherever possible.",
"        </p>",
"        <p>",
"         Design traffic flow patterns and waiting areas to respect patients' privacy and need for conversational areas.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emotional support and alleviation of fears and anxiety",
"       </td>",
"       <td>",
"        <p>",
"         Is the patient worried about his or her illness or its effect on the ability to care one's self or one's family?",
"        </p>",
"        <p>",
"         What are the principal stresses in the patient's life?",
"        </p>",
"        <p>",
"         Is he or she worried about paying medical bills or about lost income due to illness?",
"        </p>",
"        <p>",
"         Does the patient have access to appropriate support networks to help with these worries?",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Make videos on simple relaxation techniques available to patients to help them cope with medication side effects or stressful procedures.",
"        </p>",
"        <p>",
"         Review with patients the kind of information, assistance, and support they need and the approaches they find most helpful; make this a routine part of the history and physical.",
"        </p>",
"        <p>",
"         Identify or develop educational materials suited to patients' varied coping styles.",
"        </p>",
"        <p>",
"         Use focus groups or other methods of eliciting feedback from different types of patients to develop appropriate protocols and materials for administering the Patient Self-Determination Act.",
"        </p>",
"        <p>",
"         Using focus groups or other methods of patient involvement, plan services and programs with the same concern for patients' psychological and emotional needs that is devoted to their physical requirements.",
"        </p>",
"        <p>",
"         Identify patients with a serious illness or chronic disability and members of their families who are willing to share their experiences with others newly diagnosed.",
"        </p>",
"        <p>",
"         Give patients written information about available support and self-help groups.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Involvement of family and friends",
"       </td>",
"       <td>",
"        <p>",
"         Are family and friends included appropriately in planning and providing care?",
"        </p>",
"        <p>",
"         Do they have the support they need?",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Make appropriate staff available to counsel, educate, or meet with patients' family members; inform families of their availability.",
"        </p>",
"        <p>",
"         Encourage family members to write down or express their concerns; include these family notes in the patient's record.",
"        </p>",
"        <p>",
"         Offer families written or videotaped take-home materials with health information appropriate to their needs.",
"        </p>",
"        <p>",
"         Identify appropriate family support and referral services in your community.",
"        </p>",
"        <p>",
"         Train volunteers to visit the patient and family at home to help with unanticipated home care needs, such as filling prescriptions, running errands, coordinating home care services, or providing referrals to community resources.",
"        </p>",
"        <p>",
"         Develop appropriate protocols for assessing the needs of families of patients with serious or chronic ailments.",
"        </p>",
"        <p>",
"         Include patients and family members on committees or task forces to plan or evaluate clinical services.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transition and continuity from one locus of care to another",
"       </td>",
"       <td>",
"        <p>",
"         Do the patient and family understand medications to take, treatment regimens to follow, activities to pursue or avoid, and danger signals to look out for?",
"        </p>",
"        <p>",
"         Are there clear plans for continuing care and treatment?",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Identify the post-hospital needs of patients scheduled for hospitalization prior to their admission.",
"        </p>",
"        <p>",
"         Identify or design educational services that teach patients what they need to know to care for themselves away from the clinical setting.",
"        </p>",
"        <p>",
"         Encourage patients to write down their questions; make sure those questions are answered before they leave the hospital or clinic.",
"        </p>",
"        <p>",
"         Audiotape conversations at critical junctures of the patient's treatment and give patients a copy of the tape to take home.",
"        </p>",
"        <p>",
"         Make use of nursing or social work case managers to help coordinate care across sites or specialities.",
"        </p>",
"        <p>",
"         Designate staff to telephone patients after critical office visits or discharge from the hospital.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27422=[""].join("\n");
var outline_f26_49_27422=null;
var title_f26_49_27423="Outcome beta blocker amiodarone";
var content_f26_49_27423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68950%7ECARD%2F55671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68950%7ECARD%2F55671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Beta blocker plus amiodarone improves survival after a myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 313px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pooled analysis of patients in the EMIAT and CAMIAT trials shows that all-cause mortality after a myocardial infarction is lower with a combination of amiodarone and a beta blocker compared with beta blocker alone or no beta blocker with or without amiodarone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Boutitie F, Boissel JP, Connolly SJ, et al. Circulation 1999; 99:2268.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benefit of beta blocker plus amiodarone after myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 231px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pooled analysis of patients in the EMIAT and CAMIAT trials shows that all-cause mortality, arrhythmic death, rescucitated cardiac arrest, and non arrhythmic cardiac death were reduced in patients taking beta blocker; the decrease was most prominent in those treated with the combination of beta blocker and amiodarone.",
"    <div class=\"footnotes\">",
"     Pl: placebo; Am: Amiodarone.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Boutite F, Boissel JP, Connolly SJ, et al, and the EMIAT and CAMIAT Investigators. Circulation 1999; 99:2268.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_49_27423=[""].join("\n");
var outline_f26_49_27423=null;
